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Abstract 
 
Despite successful induction chemotherapy, most patients with acute myeloid leukemia (AML) will 
relapse. Immune surveillance by T cells or natural killer (NK) cells may play a role in preventing 
relapse. This thesis examines the potential of NK cells to control AML. 
Study 1 explored in 248 patients with haematological malignancies from the US National Institutes 
of Health, the genetic diversity of NK killer immunoglobulin receptor (KIR) genes in patients and 
their stem cell donors and their impact on outcome after stem cell transplantation (SCT) for 
haematological malignancy. Individuals with AML receiving SCT from donors inheriting 3 
particular B-haplotype KIRs were 4 times less likely to relapse than those with donors without these 
favourable KIRs. 
Study 2 explored in samples obtained from 499 patients enrolled on UK MRC/NCRI AML trials, 
whether KIR genotype affects the risk of developing AML or the outcome of remission induction 
chemotherapy. While KIRs had no effect on the development or outcome of de novo AML, 
individuals with more activatory KIRs, in particular 2DS2, developed significantly less secondary 
AML, suggesting that activatory KIRs can protect against secondary AML. These studies support a 
role for NK-mediated immune surveillance in AML. 
Study 3 investigated the phenotype and function of AML NK cells. In 32 prospectively collected 
samples from AML patients undergoing remission induction chemotherapy at the Hammersmith 
Hospital, AML patients were found to have reduced NK activatory receptors, increased NK 
inhibitory receptors, and reduced cytotoxic function towards leukaemia, compared to healthy donors. 
These abnormalities corresponded with failure to achieve remission and can be induced in normal 
NK incubated with AML blasts.  
I conclude that KIR genetics have a limited influence on AML development and outcome but that 
AML itself can impair NK function, reducing the chance of achieving remission. These findings 
have implications for NK based immunotherapy for AML.  
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Chapter 1 Introduction 
 
Increasing evidence suggests that natural killer (NK) cells are an important part of the immune 
response against leukaemia, yet the mechanisms mediating this anti-leukaemia response remain 
mostly unclear.  A better understanding of this response could help us exploit and/or augment NK 
immunity to improve outcome for patients. The aim of this PhD project is to investigate the innate 
immune response to acute myeloid leukaemia (AML) by asking three main questions: 
1. Do individual killer immunoglobulin receptor (KIR) genes (coding for specific NK surface 
receptors) affect the risk of developing leukaemia and the outcome of treatment aimed at 
cure, ie. chemotherapy and stem cell transplantation? 
2. Are NK cells abnormal in surface phenotype or cytotoxic function in AML patients and does 
the individual’s NK cell receptor profile or cytotoxicity affect outcome of leukaemia 
remission induction treatment? 
3. Are abnormalities found in NK cells induced by the AML or do they occur because of genetic 
predisposition?  
 
1.1 Leukaemia 
Leukaemia accounts for over 4000 deaths/year in the UK and is one of the few cancers to affect 
young people. Due to accumulation of malignant cells in the bone marrow, the production of normal 
blood cells is impaired and patients typically present with anaemia, infections and bleeding. Without 
treatment, patients with acute leukaemia usually die from their disease within a matter of weeks. 
The last 40 years have brought great improvements for children with acute leukaemia but outcomes 
remain worse for adult patients. Current treatments with chemotherapy and/or stem cell 
transplantation bring remission to over 80% of adults with acute leukaemia. However, despite this 
improvement, more than 50% will relapse within the first three years.1-3 
Prognostic factors predicting outcome of treatment for AML have evolved from morphological 
classifications to include cytogenetic and molecular characteristics of the disease. This enables us to 
categorise AML into three broad risk categories– favourable, intermediate and adverse risk (table 
1.1).  
However, since treatment success varies within these leukaemia-defined risk factors, other influences 
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both environmentally and genetically determined appear to play an important role in determining 
leukaemia treatment outcomes. One prognostic factor deserving further exploration is the role of the 
immune system in controlling the leukaemic process. 
Table 1.1 Standardised reporting for correlation of cytogenetic and molecular genetic data in Acute 
Myeloid Leukaemia with clinical data according to the ELN Guideline4  
ELN Genetic Risk Group Subsets 
Favourable  
 
t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); 
CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal 
karyotype) 
Mutated CEBPA (normal karyotype) 
Intermediate-I Mutated NPM1 and FLT3-ITD (normal 
karyotype) 
Wild-type NPM1 and FLT3-ITD (normal 
karyotype) 
Wild-type NPM1 without FLT3-ITD (normal 
karyotype) 
Intermediate-II Cytogenetic abnormalities not classified as 
favourable or adverse 
Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-
EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
-5 or del(5q); -7; abnl(17p); complex 
karyotype 
Abbreviation:ELN=European LeukaemiaNet. 
 
It is increasingly recognised that interactions between the immune system and malignant disease are 
important at all stages from disease predisposition (immune regulation) to the success or failure of 
treatment (involving “immune editing “ of the immune system by the malignancy and “immune 
20 
 
escape” where changes in the malignancy allow it to evade immune detection and destruction.) 
When considering the immune response to malignancy and leukaemia in particular there is evidence 
for both humoral and cellular immune interactions with leukaemia involving both innate and 
adaptive immunity.  
 
1.2 Innate and adaptive immunity 
The division of the immune system into innate and adaptive immunity can be a helpful way of 
describing two complementary sides to our immune armoury. Innate immune cells include dendritic 
cells and monocytes as well as natural killer cells, which can exert rapid effector function through a 
limited repertoire of germ-line encoded receptors, which are not antigen specific. While less specific, 
the innate system responds immediately to many common immune stimuli including infections and 
malignant cells. Adaptive immunity requires more time but can mount highly specific and repeatable 
responses to almost any foreign pathogen we might encounter. Adaptive immunity is mediated 
through T and B cells both of which express a large repertoire of antigen receptors, which are 
produced via somatic recombination following exposure to antigens in specialised lymphoid organs 
where they develop from naïve into mature effector cells.  
 
1.3 Immune surveillance 
The concept of immune surveillance of malignant disease (that is, the immune system constantly 
searching, detecting and eradicating emerging malignant cells) is widely accepted.5-7 The process of 
immune surveillance involves two components (1) The role of the immune system in preventing the 
development of malignant disease and (2) The behavior of the immune system in the face of an 
established malignancy. Initial evidence for involvement of the immune system in the prevention of 
malignancy comes from the increased risk of malignant disease seen in immune deficient 
individuals. While there is abundant evidence for immunosuppression predisposing to lymphoid 
malignancy8,9 the only evidence in man for the role of an intact immune system protecting against 
AML comes from a recent observation that patients receiving long term immunosuppression 
following solid organ transplants have a 2 and 5 fold higher risk of developing AML after renal or 
cardiac transplant respectively.10  
In the face of an established AML there is evidence for both immune editing and immune escape 
(discussed further in sections 1.9 and 1.10). T cells and NK cells from patients with AML are unable 
to synapse normally with AML blasts.11 Immunosuppressive regulatory T cells are increased in 
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AML,12 and superior NK cytotoxicity against leukaemia targets (as assessed by % lysis of blasts) is 
associated with an improved leukaemia free survival.13 There is also a growing body of literature 
associating robust lymphocyte recovery after remission induction for acute myeloid leukaemia 
(AML) with improved survival.14,15 However, it is unclear which lymphocyte subset is implicated in 
this association. Certainly, both T cells and NK cells are implicated in the powerful graft-versus-
leukaemia (GVL) effect observed after allogeneic stem cell transplantation (SCT),16,17 a setting 
which, by transplanting a healthy immune system into an immunodeficient host provides an 
important model for the role of the immune system in controlling any residual or re-emerging 
malignant disease.  
 
1.4 Graft versus leukaemia 
Extensive evidence for T cells in the graft versus leukaemia effect18 follows initial observations that 
SCTs depleted of T cells were associated with increased relapse rates19 and that donor lymphocyte 
infusions could promote remission after relapse.20 In order for T cell-mediated GVL to occur, T cells 
must recognise antigens on the leukaemia cell. These antigens can be either leukaemia-specific 
(LSA) or minor histocompatibility antigens (mHag): found on most tissues or restricted to 
haematopoetic tissues.21 LSA range from aberrantly expressed proteins such as neutrophil elastase 
and proteinase 3, to tumour specific proteins such as BCR-ABL in chronic myeloid leukaemia, 
Wilms tumour 1 (WT1) and preferentially expressed antigen of melanoma (PRAME) which can act 
as antigens and stimulate a cytotoxic T cell response.22 A third piece of evidence for T cell GVL is a 
fascinating mechanism of tumour evasion whereby relapsed leukaemia cells after haplo identical 
SCT can down regulate expression of the whole mismatched haplotype, therefore expressing only the 
matched haplotype and thus avoiding T cell (but not NK cell) recognition.23 
 
Initial evidence for NK cell-mediated GVL came from data showing that SCTs mismatched for NK 
KIR ligands were associated with reduced relapse.24-26 Further evidence of NK alloreactivity has also 
been documented in HLA identical SCT without inhibitory KIR-ligand mismatch suggesting a role 
for activatory KIRs in the process.27-29 One particular benefit of the NK-mediated GVL effect post 
SCT is that unlike T cell responses, NK reactivity does not appear to be associated with an increased 
risk of graft versus host disease (GVHD), that is, an unwanted immune response targeting normal 
tissues such as skin, gut and liver. On the contrary, NK cells are thought to reduce the risk of GVHD 
by attacking host dendritic cells leaving fewer opportunities for antigen presentation to T cells from 
the incoming graft.26 
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The question of whether T cells or NK cells are primarily responsible for effective immune 
responses against AML is not yet resolved. It is possible that both NK cells and T cells exert some 
control over residual leukaemia after remission induction or that in different subsets of AML either T 
cells or NK cells predominate in their antileukaemic effect. Certainly much less is known about NK 
cell responses to leukaemia. The genetic KIR data above implicates NK cells in a useful graft versus 
leukaemia effect post SCT, indicating that an NK-mediated anti-leukaemic effect is present and 
therefore further knowledge is desirable. In this thesis I focus on the natural killer (NK) cell immune 
response to AML. 
Below, I review current knowledge on the biology of NK cells and the mechanisms of cytotoxicity 
against leukaemia and discuss what we know about immune editing and immune escape in the 
context of both allogeneic and autologous NK cell interactions with AML. 
 
1.5 NK cells 
Natural killer (NK) cells are large granular lymphocytes, which normally make up 2-10% of the 
circulating lymphocyte population (fig. 1.1). Their main function appears to be to kill unwanted 
infected or malignant cells. They also play a role in maintaining the developing embryo in utero.30 
                                                
Figure 1.1 Morphological features of an NK cell under light microscopy (hematoxylin and eosin stain) 
 
1.6 Cytotoxic mechanisms of NK cells 
NK cells, by directly killing malignant cells, are believed to play an important role in the immune 
response against leukaemia. They kill by using perforin to deliver granzymes into target cells, and by 
using death receptor pathways such as TRAIL and Fas ligand. NK cells also secrete cytokines such 
as interferon gamma (IFNγ) and tumour-necrosis factor alpha (TNFα) (fig. 1.2).  
NK cell 
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Figure 1.2 Different mechanisms of NK mediated cytotoxicity (derived from Frontiers in Bioscience 10, 
1396-14, 2005). 
1.6-i Granule dependent pathway-perforin/granzyme release (CD107a) 
NK cells and CD8 T cells contain cytoplasmic vesicles or granules, which store the preformed lytic 
molecules perforin, granzymes and granulysin. Protease enzymes are made and stored in an inactive 
stage within the vesicle.31 The wall of these granules contains a range of lysosomal-membrane-
associated glycoproteins including CD107a, which protect the NK cell from the granule contents. 
When a target cell is recognised, the granule is mobilised along microtubules towards the synapse 
with the target cell. The microtubules then realign to ensure polarised delivery of the granules 
specifically to the synapse.32 Degranulation then occurs when the lytic contents are released at the 
target by exocytosis.33-35  
Released perforin anchors to the target cell membrane via its C terminal domain where, in the 
presence of calcium, polymerization occurs and its lytic N terminal domain begins to form 5-20nm 
cylindrical pores in the target cell membrane.36-38 These pores allow entry to granzyme and 
granulysin and also ionic exchange causing an osmotic imbalance and cell death.36 There is also 
evidence that granzymes enter the target cell independently of perforin.39,40 The importance of 
perforin in the immune response is supported by studies showing that perforin-deficient mice 
develop lymphoma41 as well as the familial haemophagocytic lymphohistiocytosis (HLH) syndrome 
in humans, where an inherited mutation in the perforin gene is associated with extensive immune 
suppression, particularly to infections caused by intracellular pathogens.42 Granzymes, most 
abundantly granzyme A and granzyme B, once inside the target cell, trigger apoptosis via a cascade 
1 
2 IFN
γ 
3 
4 
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of mechanisms including activation of the endoplasmic reticulum complex, an increase in reactive 
oxygen species, breaching of the cell nucleus and mitochondrial outer membrane and fragmentation 
and degradation of chromosomal DNA. Much of this activity is dependent on caspases found in the 
target cell cytoplasm.43 
1.6-ii Death receptor pathways- Fas Ligand (FasL) and TNF related protein (TRAIL) 
NK cells and other effector cells such as T cells, express surface FasL. Target cells (such as many 
AML blasts) which express Fas, are therefore susceptible to apoptosis via the Fas-FasL death 
receptor pathway. This pathway was first recognised in perforin-deficient mice as an important 
mechanism of killing independent to the perforin granzyme pathway, first in T cells and then NK 
cells.44,45  
FasL is stored at high levels intracellularly but normally expressed at low levels on the surface of NK 
cells.46 Preformed FasL is stored on the inner surface of NK granules, which also contain perforin 
and granzymes.46 Upon activation of an NK cell via its activatory receptors, surface FasL is 
upregulated within 60 minutes.47 Binding of FasL to Fas on a target cell leads to trimerisation and 
recruitment of Fas-associated death domain proteins (FADD). This leads to a cascade of caspase 
activation and cytochrome C production leading to DNA cleavage and cell death.48 A similar 
mechanism leads to apoptosis when TRAIL binds its receptors DR4 or 5.49-51 There is evidence that 
NK cells use different cytotoxic mechanisms depending on their degree of maturity and site of 
action. TRAIL is primarily used by more immature NK cells52 and perforin-mediated cytotoxicity 
has been shown to be more effective in the spleen than the liver,53 suggesting that NK cells may 
change with development and alter their mechanism of action depending on the environment. 
Interestingly, high levels of FasL are constitutively expressed in immune privileged sites such as 
cells of the brain, testes and eye where it has been shown to be part of the immune tolerance 
mechanism at these sites.54 Both the Fas and TRAIL death receptor pathways have been shown to be 
important in NK mediated killing of tumor cells.55-58 
1.6-iii-Secretion of interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α) 
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine which was named following the initial 
finding that it caused rapid haemorrhagic necrosis in tumours transplanted into mice.59 Since then, as 
well as necrosis, it has been shown to play a role in a range of cellular activities including 
proliferation, differentiation, apoptosis and induction of other cytokines.60-62 TNF-α is produced as a 
26kDa trans-membrane precursor which is converted to its soluble form upon release via cleavage by 
ADAM-17 protease.63 Its role in NK cell cytotoxicity is mediated by binding to TNF receptor 1 
(TNFR1) on a target cell, leading to the recruitment of a number of proteins including TRADD (TNF 
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R1 associated death domain protein) and FADD/MORT1 (Fas-associated death domain protein), 
which induce apoptosis via a caspase cascade. Its inflammatory, immune regulatory and cytokine-
inducing roles are mediated through the NF-κB and MAP kinase pathways after binding to TNF R1 
and/or TNF R2.64 
Interferon-gamma (IFN-γ) is produced by NK cells on target cell recognition, as well as in response 
to exogenous cytokines such as interleukin (IL)-2, 12, 15 and 18.65 IFN-γ production by NK cells has 
a number of roles. As well as facilitating NK killing of tumour66 and virally infected cells,67 it also 
has an immunoregulatory role. In the latter capacity it has been shown to be important in dendritic 
cell homeostasis68 and promoting priming of CD4 Th1 cells,69 as well as having anti-inflammatory 
properties (in mouse arthritis models it has been shown to prevent neutrophil recruitment to affected 
joints.)70 TNF-α and IFN-γ are produced de novo in the golgi body of the NK cell after contact with a 
target cell. They are then trafficked via a recycling endosome to the cell surface for release. These 
carriers transport the cytokines all over the cell surface, as well as to the target cell synapse,71 as 
befits the multifunctional role of TNF-α and IFN-γ in triggering other immune cells as well as 
directly influencing target cell death.  
 
1.7 NK cell receptors  
NK cell receptors provide a means by which NK cells can recognise and differentiate potential 
targets from normal cells. Each NK cell has a range of receptors on its surface. Engagement of these 
receptors with their ligand on a target cell, will either result in the activation or inhibition of NK 
activity.  The balance between activating and inhibitory receptors determines whether target cell 
killing occurs. Important families of NK receptors include the C-type lectin family (including 
NKG2A and D), the natural cytotoxicity receptor (NCR) family, which includes NKp46, NKp44 and 
NKp30, the signal lymphocytic activating molecule (SLAM) family which includes CD244, NTB-A, 
and CRACC, as well as CD16 and the killer immunoglobulin (KIR) receptor family. Known ligands 
for these receptors are shown in figure 1.3 below. 
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Figure 1.3 NK receptors and their ligands (derived from Vivier et al.72) 
 
1.7-i-C-type lectin receptors 
The NKG2 family of NK receptors are type two glycoproteins encoded for by genes located in the 
NK complex on chromosome 12. The NKG2 genes (unlike, for example, KIR genes) have limited or 
no polymorphism and receptor function has been shown to be unaffected by the minor allelic 
variants.73 NKG2-A, -B, -C, -E and -F form heterodimers with the CD94 molecule. They are either 
activatory or inhibitory depending on the molecules found in the cytoplasmic region of the NKG2 
part of the complex.  
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The inhibitory receptor NKG2A has an immunoreceptor tyrosine-based inhibitory motif (ITIM) and 
inhibits NK killing when triggered.74,75 Receptors containing an ITIM function via the 
phosphorylation of the tyrosine residue (probably by a Src family kinase), which results in 
recruitment of the lipid phosphatase SHIP (Src homology 2 domain-containing inositol-5-
phosphatase) or the tyrosine phosphatases SHP-1 (SH2-containing protein-tyrosine phosphatase-1) 
or SHP-2.76 These phosphatases, when recruited to the synapse between an NK and a target cell 
where activatory receptors are also located, inhibit NK responses by dephosphorylating the protein 
substrates of the tyrosine kinases linked to NK activatory receptors, thereby inhibiting calcium 
influx, degranulation, cytokine production and NK proliferation.77 The ligand for NKG2A is HLA 
E.78 NKG2A has also been shown to over-ride NK activatory signals by disrupting the formation of 
the normal actin cytoskeleton in the immune synapse of NK cells.79  
 
In contrast to NKG2A-mediated inhibition, NKG2C, D and E lack ITIMs and transmit activating 
signals.80 NKG2C has a 12kDa DNA activating protein (DAP-12) which contains an 
immunoreceptor tyrosine-based activating motif (ITAM).81  
 
NKG2D does not form a dimer with CD9482 and lacks an ITAM but forms an activating receptor 
complex with DAP-10.83 This contains a binding site for the recruitment of the phosphatidylinositol 
3-kinase (PI3K) through which activatory signal transduction occurs.82,84 NKG2D recognises the cell 
surface glycoproteins MHC class-I-chain-related protein A (MICA), MICB and UL-16 binding 
proteins 1-4 (ULBP).85,86 These molecules are structurally similar to MHC class 1 but do not have 
antigen presenting function. Expression of the ligands for NKG2D increases in ‘stressed’ cells87 such 
as virally infected or tumour cells and modified expression of these ligands form part of the immune 
evasion technique employed by tumours (see sections 1.9 and 1.10 below).  
1.7-ii-Natural Cytotoxicity Receptors (NKp30, NKp44, NKp46) 
Natural cytotoxicity receptors (NCRs) are restricted to NK cells.88 They are glycoprotein receptor 
members of the immunoglobulin superfamily whose names reflect their molecular size (30, 44 and 
46 kDa respectively). The genes for the NCRs map either to the leukocyte receptor complex on 
chromosome 19 (NKp46) or to the TNF cluster of the MHC gene complex on chromosome 6 
(NKp30 and p44). These activating receptors do not themselves contain ITAMs but couple to 
molecules such as CD3ζ, FcεRIγ and DAP12, which do.89 This enables activatory signaling via 
phosphorylation of the ITAM tyrosine by Src family kinases and binding of the tyrosine kinases Syk 
and ZAP-70.77 The ITAM activation results in actin cytoskeleton reorganization and NK granule 
release as well as transcription of cytokine and chemokine genes.  
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Despite the fact that the NCRs were discovered to be a separate group of NK activating receptors 
some years ago,90-93 little is known about their ligands. There is evidence that viral haemagglutinins 
can trigger NCR-mediated activation94-96 but their ability to activate killing of non-virally infected 
cells indicates cellular ligands which are still unknown. To date, only one tumour ligand has been 
found for NKp30, the stress-induced self molecule B7-H6.97 
1.7-iii-SLAM family receptors 
These include the immunoglobulin-related protein CD244, NTB-A and CRACC. They all contain 
Thr-x-Tyr-x-x-Leu/Ile motifs in their cytoplasmic tail and activation signals occur via SH2 
containing adaptor proteins (Ma 07). The ligand for CD244 is CD4898,99 which is highly expressed 
on EBV infected cells. 
1.7-iv-CD16 
CD16 was the first NK activating receptor to be identified.100,101 It is a low affinity Fc receptor for 
IgG and mediates antibody dependent cellular cytotoxicity (ADCC). CD16 signals via its association 
with the ITAM- containing CD3ζ102 and/or FcεRIγ103 molecules.                  
1.7-v-Killer-immunoglobulin-like-receptors (KIRs) 
One of the most important families of NK cell receptors is the KIRs. KIRs recognise class I HLA (A, 
B or C) ligands on normal cells. The names of KIR genes reflect the structure of the protein they 
encode. KIR proteins have either two or three immunoglobulin-like domains (therefore genes are 
named either KIR2D or KIR3D) as well as either short or long cytoplasmic tails (named KIR2DS or 
KIR2DL). The final part of the name numbers the genes within each structural subset (i.e.KIR2DS1, 
KIR2DS2 and KIR2DS3) (fig. 1.4). Long cytoplasmic tails contain two immune tyrosine-based 
inhibitory motifs (ITIM), which transduce inhibitory signals via SHP-1 to the NK cell. Short 
cytoplasmic tails contain a positively charged amino acid residue in the transmembrane region which 
allows them to associate with a DAP12 signalling molecule capable of generating an activation 
signal.104 The activating KIR arose by gene duplication and conversion from inhibitory 
receptors105,106 and therefore have very similar extracellular domains to their inhibitory counterparts, 
sometimes only differing in one amino acid. This fact makes finding monoclonal antibodies to 
distinguish between activating and inhibitory KIR extremely difficult, for most, only antibodies 
binding both are available. 
The ligands for KIRs are class 1 HLA molecules. Each NK cell appears to have at least one MHC-
specific inhibitory receptor, which recognises a ligand on every self cell, preventing killing of normal 
healthy cells.107 Leukaemic and infected cells have been shown to down regulate these ligands, in an 
attempt to avoid T cell immunity, making them a particular target for NK killing.108  
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The 15 KIR genes and 2 pseudogenes are located on chromosome 19q13.4 (fig. 1.5). Certain 
‘framework’ genes (3DL3, 3DP1, 2DL4 and 3DL2) are inherited by all individuals. Studies 
involving family segregation analysis have identified two KIR haplotypes. Haplotype A has a fixed 
combination of genes KIR2DS4, KIR2DL1, KIR2DL3, KIR3DL1 and KIR3DL2, whereas haplotype 
B involves significant inter-individual variation and can include between one and five of the genes 
KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1.109 
NK clones express particular KIRs randomly selected from available inherited genes so that an 
individual will have different subsets of circulating NK cells with specificity for different HLA 
ligands.110 There is evidence that self tolerance is augmented by an ‘education’ process which occurs 
during NK development, during which NK cells require interaction with self MHC to become fully 
functional111-113 as discussed below. 
 
 
    
Figure 1.4 KIR protein structure from Immunopolymorphism Database (IPD) http://www.ebi.ac.uk/ipd 
30 
 
 
Figure 1.5 KIR genes in the LRC on chromosome 19 (derived from Kulkarni et al114) 
1.7-vi-The balance between NK activatory and inhibitory receptors 
Importantly, the signaling for NK inhibitory receptors is localised and transient and if the NK cell 
subsequently encounters a new target without the ligands for inhibitory receptors, activation can 
occur.77 Activatory receptors appear to work in combination, with signals often providing additive or 
synergistic effects115 enabling a critical threshold of activation to occur in order to override any 
inhibitory signaling (which normally predominates in order to provide self tolerance). 
 
1.8 NK development and education/tolerance 
As with other lymphocyte subsets, NK cells are derived from CD34+ haematopoetic stem cells 
which are primarily found in the bone marrow.116-118 However, in contrast to clear evidence for 
different stages of maturation of T cells in the thymus and of B cells in the bone marrow, the site and 
process of NK cell maturation is less clear. As well as bone marrow, studies isolating immature NK 
cells with high surface expression of CD56 from lymph nodes and tonsils have identified these sites 
as also likely to be important for NK maturation.119-121 However, the details of the site and sequence 
of NK development are not, as yet, entirely clear.  
1.8-i-CD56 
Otherwise known as neural cell adhesion molecule (N-CAM) or Leu-19, CD56 is found on the 
surface of all NK cells although its precise function is unknown.122 Some early studies indicated that 
it might be important in target cell recognition123,124 although more recent work indicates that other 
receptors appear to be more important in this role (as detailed above). CD56 is, however a useful 
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marker in helping to categorise different subsets of NK cells. It is known that NK cells express 
surface CD56 in different densities and can be categorised as CD56 bright or dim. These two NK 
subsets differ in their localization125 and in their functional ability.126 CD56 bright cells encompass 
approximately 10% of peripheral blood NK, being mostly localised to the lymph nodes and tonsils. 
They do not express perforin127 and are thought to be primarily cytokine secreting, producing IFNγ 
in response to stimulation with IL-12, IL-15 and IL-18.125 In contrast, CD56 dim NK cells make up 
90% of circulating NK cells and are cytotoxic, expressing perforin and producing IFNγ in response 
to tumour cells.125 These features suggest that there is a gradient of maturity with high expression of 
CD56 denoting early NK cells which lose high expression of CD56 as they move into the peripheral 
blood and become better cytotoxic killers.128-130 There is also evidence that the tonsils and lymph 
node tissues are the site for development of a CD56 bright population of NK cells from initial 
CD34+ stem cell NK precursors to mature CD56 bright NK.121,131 Whether precursor NK cells 
migrate to the tonsils and lymph nodes from the bone marrow and peripheral blood for maturation or 
are produced here de novo is yet to be confirmed. 
1.8-ii-KIR ligands and NK education/ tolerance 
The role of major histocompatibility complex (MHC) molecules in NK function was first brought to 
light in a paper by Karre et al describing how NK cells kill cells that are lacking MHC molecules, in 
contrast to T cells which identify foreign proteins when they are bound to MHC.132 This ‘missing 
self’ hypothesis, required all NK cells to possess an inhibitory receptor that could bind MHC class 1. 
As MHC are expressed on virtually all healthy cells, this prevents NK cells being activated under 
normal conditions.108 These MHC class 1-recognising receptors were subsequently identified,133,134 
their genes encoded135 and the human receptors labeled as KIRs.136 That NK cells do not attack the 
few normal circulating cell types which express no or low levels of MHC (eg. red blood cells and 
neurons) was later explained by the fact that NK cells also require triggering of their activatory 
receptors to kill.137-140 However, as discussed above, the exact ligand for many of these activatory 
receptors is still unknown. In a similar manner to the way in which T cells are educated, NK cells are 
also influenced by exposure of their activatory receptors to ubiquitously expressed viral or self 
ligands during development. Exposure downregulates receptor function, as well as partially deleting 
the autoreactive cells.141-143 Interestingly, this ‘tolerisation’ process, when occurring via the NKG2D 
receptor has been shown to also induce reduction in function of other activatory receptors indicating 
‘cross tolerisation’ between receptors.144 
One area of NK biology which has had increasing attention in recent years, is the role of KIR ligands 
in NK education. These interesting studies, first in mice,145,146 then in humans,147 showed that KIR-
expressing NK cells require exposure to the ligands of their inhibitory KIRs in order to become fully 
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functional, a process termed ‘licensing’. Further studies looking at the activatory KIR 2DS1 (which 
binds HLA C2 as its ligand), have shown that exposure of an activatory KIR to its ligand during 
development also plays a role. KIR2DS1+ NK cells are hyporesponsive against targets in 
homozygous HLA C2 individuals,148 indicating activatory KIRs also have educational value but in 
the opposite direction to that of inhibitory KIRs, towards maintaining tolerance to self  rather than 
facilitating cytotoxicity. 
The process of NK education is not uni-directional or restricted to the environment in which the NK 
cell develops. Studies transplanting normally functioning mature NK cells into MHC class 1-
deficient hosts, show that they become anergic several days after transfer.149 Conversely NK cells 
from MHC-deficient hosts (which were as expected, hyporesponsive, having never been ‘licensed’), 
become responsive after transfer into MHC expressing hosts.150 The exact location of this process is 
as yet unknown. The plasticity of NK maturity and the role of circulating ‘unlicensed’ NK cells, 
which are not destroyed as equivalent T cells are, may interestingly be of use in the response to viral 
infections. Murine work has shown recently that unlicensed NK cells are actually better effectors 
against murine CMV than licensed NK cells,151 suggesting that licensing by inhibitory receptors, 
while important for tolerance and education, may inhibit response to viral infections.  
 
 
1.9 Immune editing-the effect of leukaemia on the immune system 
As introduced in section 1.2, tumour immune surveillance is likely to be important in leukaemia 
development: possessing an intact immune system to ensure that any emerging tumour cells are 
rapidly recognised and destroyed is an important part of remaining malignancy-free. It is perhaps 
expected therefore, that tumours might try to overcome this process and there is evidence to illustrate 
that tumour cells can induce changes to an otherwise healthy immune system, which facilitate their 
survival. 
These include secretion of soluble factors by tumour cells which inhibit immune cells. For example, 
production of transforming growth factor beta (TGFβ) reduces NKG2D and NKp30 expression and 
consequently reduces killing of certain tumour cell lines.152 AML cells secrete a soluble factor that 
inhibits T and NK cell proliferation but not cytolytic function.153 AML can also alter the cytokine 
production of circulating lymphoid and myeloid cells, thereby changing normal immune 
interactions.154  
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Regulatory T cells are increased in AML.12 There is evidence that AML cells may themselves be 
directly responsible for this via expression of the tyrosine converting enzyme indoleamine 2, 3-
dioxygenase (IDO).155 AML cells can also induce defects in the lymphocytes themselves: T cells 
from AML patients have abnormal phenotype and genotype and form defective immune synapses 
with AML blasts.11 Defective thymic function in AML is suggested by the fact that these patients 
have reduced levels of recent thymic emigrants.156 Furthermore, direct cellular contact between 
normal lymphocytes and AML blasts in mice results in reduced NK cytotoxicity and cytokine 
production via the down regulation of transcription factors T bet and eomesodermin, which, when 
forcibly expressed in these experiments reduces tumour size and improves survival.157 
Using a different strategy, the malignant clone itself can generate dysfunctional immune cells which 
can then go on to alter immune function: for example, producing leukaemic dendritic cells which 
present antigen but are not normal158 and inhibit induction of cytotoxic T cells inducing T cell 
anergy.159-161 Leukaemia cells can also create changes in their microenvironment optimising their 
survival, for example, producing immunosuppressive mesenchymal stromal cells.162  
 
1.10 Immune escape- changes on leukaemia induced by the immune system 
Attempts to evade the immune system by altering phenotype, that is, mutating to facilitate survival, 
is a well-known strategy adopted by viruses and bacteria. There is ample evidence to suggest that 
tumour cells also have this capacity. Perhaps one of the more well-documented mechanisms for 
immune escape of leukaemia has been the down-regulation of surface ligands which normal immune 
cells recognise. These include AML blasts expressing reduced levels of HLA molecules both pre-
treatment,163 and after haplo-identical SCT when AML can down regulate the entire mismatched 
haplotype to avoid graft versus leukaemia from mismatched cytotoxic T lymphocytes.23 Another 
example is the reduction in surface expression of MICA/B.164 A number of mechanisms and 
consequences have been reported with regard to MICA/B expression, including alteration of DNA 
modifying enzymes such as HDAC leading to epigenetic regulation and repression of MICA/B 
expression in leukaemia,165 as well as shedding of MICA/B which not only reduces ligands for NK 
cells to recognise but also, once shed, soluble MICA binds NKG2D on circulating NKs promoting 
NKG2D endocytosis and degradation and inhibiting further NK cytotoxicity.166 As well as under-
expressing ligands, leukaemia cells have been known to over express them, for example, in chronic 
myeloid leukaemia, the over expression of MICA/B induced by BCR/ ABL, causes sustained 
triggering of NKG2D and subsequent hypo-responsiveness with reduced cytotoxicity and IFNγ 
production.167  
 
34 
 
The important role of co stimulatory molecules in the immune response to leukaemia is suggested by 
evidence that a particular genotype of cytotoxic T-lymphocyte antigen 4 (CTLA-4), critical for 
maintaining T cell tolerance, is found with increased frequency in AML relapse after induction 
chemotherapy.168 That AML can weakly express co stimulatory molecules and thereby favour escape 
from T cell-mediated killing, is suggested by evidence showing a higher probability of remaining in 
remission if blasts express both CD80 and CD86.169 Altered expression of co-stimulatory molecules 
in patients relapsing with leukaemias post SCT was also associated with resistance to NK mediated 
lysis.170 Furthermore, shedding of co stimulatory molecules may also allow leukaemia to block T cell 
attack via the binding of the soluble ligand to normal T cells.171 A further mechanism for tumour 
evasion in leukaemia is to express molecules which directly inhibit immune function. For example, 
AML, in contrast to normal cells, can express the ligand for glucocorticoid-induced tumour necrosis 
factor-related protein (GITRL). Triggering through this ligand directly blocks NK function leading to 
impaired cytotoxicity and reduced IFNγ production.172 
 
In the above sections 1.9 and 1.10 I have described immune editing in leukaemia, whereby malignant 
cells attempt to alter the immune system to maintain their survival, and also select or mutate to avoid 
immune-mediated attack. This provides a framework for my PhD, which focuses on the ways in 
which these processes occur in the natural killer cell response to leukaemia. 
 
1.11 Structure of PhD project 
This thesis is laid out around three large studies. The first addresses the role of NK cell receptor 
genes in a large (n=261) retrospective observational study of matched sibling allogeneic SCT 
patients who underwent treatment at the National Institutes of Health, Bethesda, USA. This explores 
the role of KIR genetics in predicting outcome (especially leukaemic relapse) after SCT for 
leukaemia, specifically identifying a special role of NK cells in control of AML (chapter 3). Having 
identified NK genetic characteristics that were favourable for sustained AML remission after SCT, I 
carried out an analysis of KIR genotypes to address the question of whether KIR genetics could 
determine the chance of developing AML and whether KIR genetics influenced outcome after 
chemotherapy treatment. This involved a large (n=499) retrospective observational study in AML 
patients recruited to the MRC/NCRI AML 10 and 15 trials receiving chemotherapy induction 
treatment. The results are presented in chapter 4. To better understand mechanisms of immune 
editing and leukaemia escape I then carried out a prospective analysis of the role of NK cell 
phenotype and function in 32 AML patients presenting at the Hammersmith Hospital between 
September 2009 and December 2011. These results are presented in chapters 5 and 6.   
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Chapter 2 Materials and Methods 
2.1 Sample collection 
2.1.i- KIR genotype analysis in the setting of allogeneic stem cell transplantation 
These studies were performed in the Department of Stem Cell allo-transplantation at the National 
Institutes of Health (NIH), Bethesda, USA. All patients and donors had peripheral blood 
mononuclear cells (PBMC) collected and stored on institutionally reviewed and approved protocols 
for the purposes of research at the time of presentation. However, of the 261 patient-donor pairs 
transplanted and included in my project, 22 donors did not have cell samples available due to the 
usage of these samples in previous research projects. For completeness, I therefore contacted these 
donors to ask for blood or buccal swabs. This involved telephone calls (three-way with translators for 
Spanish-speaking patients) and letters. Of the 22, contact details were still valid for 11 and of these, 7 
donors agreed to send us buccal swabs of their saliva. DNA was extracted from buccal swabs by the 
HLA laboratory using the Gentra Puregene buccal cell core kit (Qiagen, Gaithersburg, MD, USA). 
Being siblings, the patient and donor populations were ethnically matched, with the majority being of 
either Hispanic or Caucasian origin.  
2.1.ii- KIR genotype analysis in the setting of chemotherapy for AML 
 All patients consented onto the AML MRC/NCRI trials have had blood samples collected by the 
patient’s clinical team at the time of treatment and sent to University College Hospital (UCH) for 
molecular diagnostics. Professor David Linch and Dr Rosemary Gale have set up a Human Tissue 
Authority approved bio-bank of all DNA extracted from AML patients on the MRC trials since 1987. 
In collaboration with Professor Linch, we applied to the MRC/NCRI for ethical approval, which was 
granted. All patient samples were linked to comprehensive outcome data. The control population was 
the normal donor population described in section 2.1.ii. This had a higher proportion of Hispanics 
than the UK MRC patient population but as their KIR gene frequency did not differ from normal 
blood donor populations collected in the UK (http://www.allelefrequencies.net/kir6002a.asp.), this 
was deemed acceptable. 
2.1.iii- Functional studies of NK cells in AML patients and normal controls 
For my prospective study of AML patients in West London, I received approval from the local ethics 
board to collect blood and marrow from newly diagnosed AML patients at Imperial College 
Hospitals (NREC reference 10/H0711/16). I consented patients and controls according to local 
protocol (see 8.1 and 8.2 in appendix for consent form and patient information sheet) and the 
samples were collected either by the clinical staff looking after the patient or myself. Samples were 
given an anonymous code as per local guidelines and material linking that code to patient identity 
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and clinical outcome data was kept in a locked drawer to which only myself had access, within the 
secure haematology research department to which access was also restricted. 
2.2 Processing, freezing and thawing PBMC 
Separating of PBMC from whole blood: Fresh whole blood was collected in EDTA and mixed 1:1 
with RPMI 1640 medium (Life Technologies, Gaithersburg, MD, USA). Lymphocyte separation 
medium (Ficoll-Hypaque, Organon-Teknika, Durham, NC, USA) was layered under the blood 
sample and the tube spun at 1800rpm for 30 minutes. The cell layer was then carefully removed with 
a sterile transfer pipette and washed in RPMI.  
Freezing: PBMC were re-suspended in 20% foetal calf serum (FCS) in RPMI complete media 
(RPMI CM containing gentamicin, glutamine and hepes) and mixed on ice with an equal volume of 
freezing media (20% Dimethyl Sulfoxide (DMSO) in 20% FCS/RPMI CM) before being 
immediately transferred to a -80ºC freezer and then to a liquid nitrogen freezer (-196 ºC) within 7 
days. 
Thawing: Cell vials were quick-thawed in a 37ºC water-bath and washed in 10% FCS in RPMI 
before resting for 1-12 hours at 37ºC prior to experiments. 
 
2.3 DNA extraction 
Genomic DNA was extracted from frozen cell samples using the Qiagen column-based method 
(Qiamp midi kit, Qiagen, Gaithersburg, MD, USA). This involved lysing cells and then loading the 
lysate onto a spin column containing a silica membrane to which the DNA binds. Impurities were 
then washed away in two centrifugation steps before pure DNA was eluted from the membrane. 
Briefly, thawed PBMC were mixed with 100µl protease and 1.2ml lyzing buffer then the sample was 
vortexed vigorously for 1 min. Lyzed cells were then incubated for 10 min in a water-bath at 70ºC. 
To optimise DNA binding to the silica membrane, 1ml ethanol was added, the sample was mixed and 
then vigorously vortexed for 1minute before being passed through the Qiamp midi column.  The 
column was then spun at 1850g (3000rpm) for 3 minutes, washed with 2ml AW1 buffer, spun, and 
washed again with 2ml AW2 buffer.  DNA was then eluted from the column into a new tube by 
adding 150µl low-salt buffer, incubating at room temperature for 5 minutes and then spinning down 
at 4500g for 2 mins. DNA concentration and purity were measured using a nanodrop machine. The 
optimal cell number to use for this method was 5 x106 cells (see appendix, supplementary table 1) 
from which DNA purity was typically >90% with a concentration of between 50-200ng/µl. 
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2.4 KIR genotyping 
KIR genotyping was performed using the Invitrogen KIR Genotyping SSP kit (Invitrogen, CA, cat. 
78930-30). This identifies the presence or absence of each of the 15 known KIR genes and 2 pseudo 
genes as well as the common variants of 2DL5, 2DS4, and 3DP1 (fig.2.1). Briefly, 0.92µg DNA was 
added to the kits buffer mixed with 1.4µl taq polymerase (Invitrogen, CA,USA) and purified water. 
8µl of this solution was added to each well, which contained a different set of sequence specific 
primers for each KIR gene. Plates were loaded onto the thermocycler (Gene amp PCR system 9700) 
and polymerase chain reaction was performed. This involved initialising for 1 minute at 95°C then 
30 cycles of denaturation at 94°C for 20 seconds, annealing at 63°C for 20 seconds and elongation at 
72°C for 90 seconds before the sample was cooled to 4°C. Each KIR gene was identified by the 
presence or absence of a band on 1.5% agarose electrophoresis gel stained with ethidium bromide (in 
USA) or SYBR safe DNA gel stain (in London) (Invitrogen, CA,USA).   
Patient HLA typing for KIR ligands was performed by the HLA laboratory, Department of 
Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA (for the NIH 
cohort) and the HLA laboratory at the Hammersmith Hospital, London (for the UK patients). Typing 
was carried out for all known KIR HLA ligands: C1 (Cw*01,03,07,08,12,13,14), C2 
(Cw*02,04,05,06,15,1602, 17,18), HLA G, HLA Bw4 (B*51,52,53,57,58, 08,13,27,37,44 and 
A*23,24,32),  A*03 and A*11. 
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Figure 2.1 Example of gel and worksheet for KIR genotyping one individual. The ladder (L) is 
positioned far left. There is a positive control at 800bp in lanes 1-19 and at 200bp in lanes 20-21. Each 
lane corresponds to primers for a particular KIR gene or allele. The work sheet shows the molecular 
weight (5th row from bottom) of each KIR gene or allele (detailed in column 2) and the gel lane where it 
is expected to be (black squares). If present, the KIR gene shows up as a distinct band of the 
appropriate molecular weight along with the positive control (see lane 1). If the KIR gene is absent, only 
the control band will show in that lane (see lane 2). Some genes require two bands. Eg. Identification of 
KIR 2DL5A (see blue arrows) requires a product of 257bp in lane 5 and 1753bp in lane 6. 
L	  	  	  	  1	  	  	  	  	  2	  	  	  	  	  3	  	  	  	  4	  	  	  	  5	  	  	  	  6	  	  	  	  	  7	  	  	  	  8	  	  	  	  9	  	  	  10	  	  11	  	  12	  	  13	  	  14	  	  	  15	  	  16	  	  17	  	  18	  	  19	  	  20	  	  21	  	  NC	   
 
 
L	  	  	  	  1	  	  	  	  	  2	  	  	  	  	  3	  	  	  	  4	  	  	  	  5	  	  	  	  6	  	  	  	  	  7	  	  	  	  8	  	  	  	  9	  	  	  10	  	  11	  	  12	  	  13	  	  14	  	  	  15	  	  16	  	  17	  	  18	  	  19	  	  20	  	  21	  	  NC	   
 
                800bp 
                200bp 
 
800bp 
200bp 
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2.5 Growing cell lines to use as NK targets and controls 
K562 is an erythroleukaemia cell line obtained from a chronic myeloid leukaemia patient in blast 
crisis. It is particularly useful as a target for NK cells as it does not express MHC class I molecules 
and therefore has no ligand for inhibitory KIR. It contains the translocation (9;22). 
Jurkat cells come from an immortalised T lymphocyte cell line, originally from a patient with T cell 
leukaemia. Unlike K562, they express Fas and can therefore be used as a control for cytotoxicity 
experiments involving Fas ligand. 
Hela cells are an adherent ovarian cancer cell line which consistently expresses the NK ligands 
DR4/5, HLA class 1 and MICA/MICB. It was used as a positive control for immunophenotyping.  
All cell lines were kindly donated from the laboratories of Dr A. Karadimitris and Dr Junia Melo. 
K562 and Jurkat cells were cultured in RPMI 1640 media with 10% FCS in culture flasks, and 
incubated at 37 ºC, 5% CO2. Hela cells were cultured in DMEM media (Gibco, UK) and harvested 
from the flask using 0.05% trypsin (Invitrogen, CA). Media was supplemented with penicillin and 
streptomycin and changed every 2-5 days adjusting cell concentration according to growth. 
 
2.6 Phenotyping NK cell surface receptors and their ligands on AML blasts 
2.6-i-Antibody staining method 
Fluorochrome-labelled, monoclonal antibodies were used to identify the expression of activating and 
inhibitory receptors on the surface of NK cells (table 2.1). Briefly, PBMC were washed with 
phosphate buffered saline (PBS) and stained with antibodies as detailed in the panels below. Stained 
cells were incubated for 20 minutes in the dark at room temperature before being washed again. The 
pellet was re-suspended in PBS and cells analyzed by 4 colour Facs Caliber Flow cytometry (BD, 
UK). Where cells were available, experiments were performed in triplicate to ensure reproducibility. 
As patient sample collection began before experiments were optimised, all our results were taken 
from frozen samples to ensure we were comparing like with like. Even so, as a precaution, a 
comparison between fresh and frozen cells for all experiments was performed to ensure that the 
freeze-thaw process did not significantly distort results (an example is shown in fig. 2.2).  
2.6-ii-Rationale for NK surface receptor antibody panel  
APC conjugated CD56 and PerCP conjugated CD3 (BD Biosciences, UK) were used to identify the 
NK cell (CD56+, CD3-) subset. A cocktail containing FITC conjugated CD33, CD34 and CD13 
(Biolegend, Cambridge Biosciences, UK) was used in every tube to efficiently separate the AML 
blast population from the NK population (fig.2.2). This step was necessary as up to 40% of AML 
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blasts express CD56173 and therefore these cells would contaminate an ‘NK’ population gated as 
CD56+ CD3- , if they were not separately gated out. This cocktail also enabled me to accurately 
identify the AML blast population to phenotype this as detailed below. Optimal concentrations of 
antibodies were decided upon using titration experiments (fig 2.3). Gating for the receptor positive 
population was set using isotype controls (fig.2.4). Where positive populations were not distinct as 
was the case with the NCRs, mean fluorescent intensity was used.174 Analysis was performed using 
Flo-jo software (© Tree Star, Inc, 1997-2012). 
Table 2.1 Antibody panel for characterising NK surface receptor phenotype 
 Tube 1 Tube 2 Tube 3 Tube 4 Tube 5 Tube 6 Tube 7 Tube 8 Tube 9 Tube 
10 
FITC CD33, CD34, CD13 
PE NKp44 NKp46 NKp30 NKG2D NKG2A KIR3DL1 KIR2DL1/S1 KIR2DL2/S2 IgG1 
isotype 
IgG2a 
isotype 
PERCP CD3 
APC CD56 
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Figure 2.2 Example of FACS plots showing the gating strategy for NK surface receptor phenotyping. 
Cells were first gated on live lymphocytes using forward and side scatter (first column), then CD56+ 
cells which were negative for blast markers CD13, 33 and 34 were identified (second column). Next NK 
cells were separated from CD56+ T cells by gating on CD3-, CD56+ cells (third column) and finally the 
NK cells were assessed for their expression of the NK surface marker of interest (forth column). This 
figure also demonstrates a comparison of fresh (top row) and frozen (bottom row) cells from the same 
patient. 
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Figure 2.3 Example of titration experiment to find optimal antibody staining for KIR antibodies. 
Serially diluted volumes of antibody were used and the lowest concentration not resulting in loss of 
signal was used in experiments. These plots show no loss of signal when using half the volume 
recommended by the antibody company. Further dilutions would then be performed. 
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Figure 2.4 Example of FACS plots showing % expression of NK surface markers (on x axis): c-type 
lectins (top two rows), natural cytotoxicity receptors (third row) and KIR (bottom row). The NK 
marker CD56 is on the y axis. Positively staining cells were identified using PE conjugated isotypes to 
identify the border with the negative population (two plots top left). NKG2A was an IgG2A antibody, 
the rest were IgG1 antibodies. 
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2.6-iii-Rationale for antibody panel characterising the expression of NK receptor ligands on the 
surface of AML blasts 
This panel (table 2.2) was used to study the expression of some of the relevant NK receptor ligands 
including Class 1 HLA (ligands for KIRs), MICA and B (ligands for NKG2D) and HLA E (ligand 
for NKG2A). I also studied the target ligands for the two death receptor pathways used by NK cells; 
namely Fas for the Fas-Fas ligand pathway and death receptors 4 and 5 (DR4/5), the ligands for 
TRAIL. The ovarian cancer cell line Hela was used as a positive control for DR4/5, MICA/B and 
HLA expression, and normal human PBMC was used as a positive control for HLA E and Fas 
expression (fig. 2.6).  
Table 2.2 Antibody panel for characterising the expression of NK receptor ligands on the surface of 
AML blasts 
        
 
Figure 2.5 Example FACS plots showing the gating strategy for blast surface phenotype. Forward and 
side scatter was used to identify live cells, then blasts were identified using CD13, 33 and 34. The blasts 
were then assessed for surface expression of the NK ligand of interest (here HLA class I). 
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Figure 2.6 Example of FACS plots and histograms from one experiment showing expression of NK 
receptor ligands on the surface of a patient’s AML blasts. Isotype and antibody staining of positive 
control cells (Hela or PBMC depending on ligand) was performed with each sample and are shown in 
the two columns to the left of the figure. The three columns to the right represent antibody staining of 
the patient’s cells. Isotype controls were used to identify the negative population (middle column and 
red line on the histogram). The blue line on the histogram represents antibody staining of patient cells. 
This patient’s blasts stained positive for the NK ligands DR4/5, HLA class 1, Fas and HLA E but not 
MICA/B. 
2.7. Purification of NK cells- Miltenyi bead column negative selection method 
This method selected NK cells from a mixed cell suspension using a cocktail of antibodies to identify 
non-NK cells (CD3, CD8, CD14 and CD4) and labeled these antibody-bound cells with metallic 
beads (NK cell isolation kit, Miltenyi Biotec GmbH, Germany). The cell suspension was then passed 
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through a magnetic column, which retained the antibody-bound cells and enabled the non-bound, NK 
cells to pass through into a tube at the bottom.  
Briefly, after thawing and performing a cell count, PBMC were re-suspended in 4 µl buffer /106 
cells. NK Cell Biotin-Antibody Cocktail was then mixed with cells at a dose of 1µl /106 cells, which 
were then incubated in the fridge for 10 minutes. Cells were then washed in 3µl buffer /106 cells and 
then 2 µl of NK Cell Micro-bead Cocktail was added/106 cells. Cells were washed in 200 µl buffer 
/106 cells before being spun and re-suspended in buffer to be passed through the negative selection 
column. CD56 +ve, CD3 –ve NK cells were collected in a falcon tube, washed, spun and counted for 
use in experiments. Typically, this technique yielded a purity of >95% NK cells (fig.2.7). 
 
Figure 2.7 Example of a FACS plot of the NK negative selection procedure from healthy donor PBMC 
using Miltenyi beads. The technique typically yields >95% NK cell purity. 
 
2.8 Purification of PBMC and blasts from AML samples at diagnosis- Miltenyi columns  
For the cytotoxicity experiments, PBMC from AML patients were co-incubated with leukaemia 
target cells. In order to use primary autologous AML blasts as targets for NK cytotoxicity, blasts 
were positively selected from PBMC collected from AML patients at presentation. The yield and 
purity using the Miltenyi selection column method described above (section 2.7) was suboptimal and 
the technique was not consistent enough to yield sufficient number of cells for the experiments. In 
order to overcome these problems, I investigated a second method, using a custom made antibody 
cocktail optimised and published by John Gribben’s group at St. Bartholemew’s hospital in 
London.175  
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2.9 Stemsep custom antibody bead selection cocktail and selection on Robosep machine  
This method allowed for positive selection of AML blasts using a cocktail of antibodies, leaving a 
population of PBMC unbound to beads or antibody. I modified the published cocktail, (which was 
initially used in experiments to select T cells) by omitting the CD11c marker, which, while found on 
a proportion of AML blasts is also found on normal NK cells. The cocktail included CD33, CD34, 
CD123 and CD36 (StemSep, Grenoble, France). The majority of AML blasts will express at least 
one and usually 2 or more of these markers. This cocktail also targets some monocytes and dendritic 
cells, making our PBMC population depleted of these cells too. In order to minimise the problems of 
high blast counts blocking the selection columns, I used a Robosep cell separator machine 
(STEMCELL technologies Inc, Grenoble, France), which has the benefit of a constant cool 
temperature and faster selection time, facilitating a greater yield of pure cell populations. This 
method consistently yielded populations of PBMC and blasts with 85- 90% purity (fig.2.8). 
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Figure 2.8 Example of FACS plots showing results of a cell separation experiment using the Robosep 
cell separator machine. Cells collected at AML presentation were separated into blast and PBMC 
populations. The blast populations (left columns) were mostly positive for pan blast markers (CD13, 33, 
34) with minimal contamination from NK (CD56+) and T (CD3+) lymphocytes. The PBMC populations 
were relatively free from AML blasts. Purity results are in brackets. AML patient 2 is an example of a 
patient whose AML blasts express the NK marker CD56. 
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2.10. NK cell cytotoxicity experiments 
PBMC were incubated with leukaemia target cells for 5 hours. NK-mediated cytotoxicity was then 
assessed by measuring the activity of the perforin/granzyme pathway (CD107a expression), cytokine 
production (intracellular IFNγ and TNFα production) and death receptor pathways (surface 
expression of Fas Ligand). I have optimised these methods as described below and in figures 2.9 to 
2.12. 
Briefly, PBMC were incubated on round bottomed 96 well plates at 37ºC, 5% CO2 in RPMI media 
supplemented with 20% foetal calf serum (final volume 200µl/well) with target cells at effector: 
target ratios of 1:1. Targets include K562 erythroleukaemia cells and autologous blasts where 
available. Effector cells were incubated without targets as the negative control and stimulated with 
PMA and ionomycin as the positive control. 
Prior to incubation, 5µl FITC conjugated CD107a monoclonal antibody (BD, UK) was added to 
wells to ensure that cell surface, as well as internalised CD107a were captured. Five µl of Monensin 
(BD GolgiStopTM Cat#554724, diluted 1:10 in PBS) was also added to ensure the vesicle PH remains 
suitable for the fluorochome and to prevent cytokine leakage. Ten µl BFA (Brefeldin A, Sigma 
Cat#B-7651, stock solution 5mg in 1mL DMSO, diluted 1:10 in PBS) was added to wells to prevent 
release of the intracellular cytokines prior to detection by the assay. After incubation, cells were 
harvested from plates and washed in PBS before surface staining with antibodies for CD3, CD56 and 
KIRs. 
After surface staining, the intracellular cytokine assay for NK production of IFNγ and TNFα was 
performed. Briefly, cells were mixed with 2ml lysing solution (BD FACS lysing solution Cat# 
349202 diluted 1:10 in dH20) and incubated in the dark for 10 minutes. Cells were then washed in 
2ml PBS before 500µl permealising solution (BD Cat# 340973 diluted 1:10 in dH20) was added and 
cells were again incubated for 10 minutes in the dark. Cells were then washed in PBS and stained 
with 2.5µl IFNγ and TNFα monoclonal antibodies (BD Biosciences, UK) before being incubated for 
30 minutes in the dark. Finally, cells were washed again and FACS analysis was performed on a BD 
LSRFortessa cell analyzer to assess the percentage of NK cells exhibiting cytotoxicity as evidenced 
by expression of CD107a, IFNγ, TNFα or FasL. The rationale for choosing these is detailed below. 
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Table 2.3 Panel for NK cytotoxicity experiments 
Laser
Fluorochrom e
Tube 1
1:1 PBMC 
K562
Tube 2
1:1 PBMC 
K562
Tube 3
1:1 PBMC 
K562
Tube 4
1:1 PBMC 
K562
Tube 5
1:1 PBMC 
K562
Tube 6
Neg C
No K562
Tube 7
Pos C
PMA/Io
488 -530 -30
FITC
BD Cat#  
555800
107a
5!l
107a
5!l
107a
5!l
107a
5!l
107a
5!l
107a
5!l
107a
5!l
488 -710 -50
Percp cy5.5
BD cat# 
641397
TNF
2.5!l
TNF
2.5!l
TNF
2.5!l
TNF
2.5!l
TNF
2.5!l
TNF
2.5!l
TNF
2.5!l
561 -582 -15
PE
KIR 
2DL1/S1
5!l
KIR 
2DL2/S2
5!l
KIR 3DL1 
DX9
5!l
Pan KIR
5!l
IgG1 iso
For KIR
5!l
Pan KIR
5!l
Pan KIR
5!l
561 -780 -60
PE Cy7
BD
CD56
3!l
CD56
3!l
CD56
3!l
CD56
3!l
CD56
3!l
CD56
3!l
CD56
3!l
640 -670 -14
Alexafl 647
AbD serotec
Cat#MCA240
9A647T
FasL
5!l
FasL
5!l
KIR 3DL1 
158e1/2
(Z27)
APC 5!l
FasL
5!l
FasL
5!l
FasL
5!l
FasL
5!l
640 -780 -60
APCcy7
BD cat# 
641397
CD3
3!l
CD3
3!l
CD3
3!l
CD3
3!l
CD3
3!l
CD3
3!l
CD3
3!l
405 -450 -50
VG450
BD 560371
IFNg
2.5!l
IFNg
2.5!l
IFNg
2.5!l
IFNg
2.5!l
IFNg
2.5!l
IFNg
2.5!l
IFNg
2.5!l
 
 
2.10.i- CD107a expression 
Measurement of surface CD107a (lysosomal-associated membrane protein-1 or LAMP-1), while 
originally developed with CD8 T cells,176 is now an established method for measuring NK 
cytotoxicity, and CD107a expression has been shown to correlate with NK-mediated target cell 
killing.177 Measuring CD107a has an advantage over standard cytotoxicity assays such as chromium 
release/ CFSE fluorescent dye release as these methods only look at death of target cells ie. the 
aftermath of NK effector function, whereas the CD107a assay enables us to identify and quantify 
effector cells. CD107a measures the granule dependent pathway of NK cytotoxicity. This pathway 
does not require de novo synthesis of proteins by NK cells (unlike IFNγ which is synthesised de 
novo) but uses pre-formed granules located in the cytoplasm. When cells are stimulated, either by 
encountering a target cell or by phorbol-12-myristate-13-acetate (PMA) and ionomycin,178 
microtubules transport the vesicle to the cell surface where the synapse with the target cell is located. 
The NK granule core (containing proteins such as perforin and granzymes) is surrounded by a lipid 
bilayer containing lysosomal associated membrane glycoproteins which include 107a (LAMP1), 
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107b (LAMP2) and CD69 (LAMP3).34,179 These proteins are also found in the lysosomal/endosomal 
membranes of other cells and are ubiquitously expressed on the surface of platelets, which may 
explain why there is usually a higher degree of CD107a background staining when PBMC are used 
as effectors rather than selected NK cells. When NK degranulation occurs, CD107a is expressed on 
the cell surface where it can be bound by fluorochrome-conjugated antibody. Re-internalization 
rapidly occurs180 but as long as antibody is added to media at the start of effector-target incubation, 
cells with even transient expression will bind antibody and this will fluoresce when re-internalised 
within the vesicle. These vesicles are acidic and could therefore potentially neutralise fluorochromes 
such as FITC; this can however, be avoided by using monensin to help neutralise the ph of the 
vesicles (as well as inhibiting the secretion of intracellular cytokines).176 
2.10.ii- TNFα and IFNγ production 
CD107a expression by NK cells is closely associated with IFNγ secretion; the majority of NK that 
produce IFNγ will also express CD107a. There is however, a separate subset of cells which do not 
secrete IFNγ but do express CD107a177 and different triggers can result in different modes of 
cytotoxicity, making the combination of these markers a more sensitive method of assessing NK 
function than one alone. As TNFα and IFNγ are intracellular cytokines, the NK cell membranes need 
to be lysed and permeabilysed to allow binding of fluorochrome labeled antibody with cytokine. This 
method therefore measures the de novo production of these cytokines in response to target cell 
stimulation over a 5 hour period (the peak period of cytokine production).181 The addition of BFA 
prevents the cytokine from being released from the cell prior to measurement. 
2.10.iii- Fas Ligand expression 
FasL is stored in NK granules and transported to the cell surface upon NK cell stimulation. As with 
CD107a, the FasL antibody is added to the culture media at the start of incubation to ensure that all 
FasL expressed on the cell surface during incubation with target cells is stained with antibody even if 
re-internalised after expression. For both CD107a and Fas L, I confirmed this by comparing different 
times for adding antibody and found that prior to incubation was optimal. 
2.10.iv- Incubation of normal NK cells with AML blasts prior to experiments 
Healthy donor NK cells were negatively selected using a NK cell negative isolation kit, (Miltenyi 
Biotec GmbH, Germany). NK cells were then cultured in 96-well plates at 250,000 cells/well with 
100 IU/mL rhIL-2 (PROLEUKIN, Chiron Corporation, Emeryville, CA.) for 24 hours, in the 
presence or absence of primary AML blasts. An NK: blast ratio of 10:1 was chosen as the most 
clinically relevant, reflecting a state of minimal residual disease. In two experiments where enough 
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cells were available, I also tested other E:T ratios and found a dose effect with higher numbers of 
blasts associated with more NK inhibition. NK were cultured for 24 hours with autologous 
mononuclear cells as another control that is not expected to alter functional activity of target cells. 
NK cells were then analysed for cell surface receptor expression, and for cytotoxicity and effector 
cytokine production against K562 leukaemia cell targets as described above. 
 
Figure 2.9 Example of FACS plots showing gating strategy for NK cytotoxicity assay 
                    
Figure 2.10 Example of FACS plots showing reproducibility of cytotoxic data.  Plots show data from 3 
separate experiments performed on 3 separate days using cells collected from the same individual on 
one day and divided into a number of vials for freezing (mean average used). 
CD56 
CD107a 
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Figure 2.11 Example of FACS plots showing one of a series of optimisation experiments. Peripheral 
blood mononuclear cells (PBMC) were incubated for 5 hours with leukaemia target cells at 
effector:target (E:T) ratios of 1:1. 3:1 and 10:1 (calculated using %NK in PBMC sample). This 
experiment and others showed NK degranulation (as measured by the number of NK cells positive for 
CD107a) was optimal at a 1:1 E:T ratio. Different numbers of leukaemia target cells were also tested: 
100,00 cells was not enough for useful results. 250,000 targets were as effective as 1 million. A negative 
control helped to define the negative population and consisted of PBMC incubated in media without 
target cells. 
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Figure 2.12 Example FACS plots showing results from one experiment assessing a patient’s NK 
cytotoxicity towards K562 (2nd and 3rd rows) and autologous blast targets (4th and 5th rows). Cells were 
incubated in media alone for the negative control and with PMA/Ionomycin for the positive control (top 
row). The y axis represents the NK marker CD56. The x axis represents the degranulation marker 
CD107a. NK cells from this patient showed very little cytotoxicity to autologous blasts. However, there 
was considerable response to K562 targets, with a greater response from KIR+ than KIR- NK cells. The 
columns represent different KIR antibodies (from left-right: 2DS1/L1, 2DS2/L2, 3DL1, Pan KIR). 
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2.11. Completing and validating the transplant database at the NIH 
Demographic and clinical details of patients undergoing SCT at the NIH were entered into a 
comprehensive computerised database by clinical staff at the time of treatment, which was further 
updated by me.  
2.12 Statistical methods 
For the transplant cohort, baseline patient characteristics and transplant outcomes were described 
using summary statistics, including means, medians, percents, standard deviations and 95% 
confidence intervals. Univariate and multivariate Cox Proportional Hazard Models were used to 
evaluate the effects of KIR genes, disease, and other factors on the cumulative distribution functions 
of time to transplant related mortality (TRM), overall survival time (OS), and time to relapse (TTR). 
Because there were multiple events per patient, our analyses included both single-event Cox 
Proportional Hazard Models and multiple-event competing risk models. For the single-event 
analysis, we considered TRM, OS and TTR separately, and used three right censoring schemes: (a) 
for the analysis of time to TRM, patients who did not die from TRM were treated as censored; (b) for 
the analysis of time to OS, patients who were alive at the last visits were treated as censored; (c) for 
the analysis of time to relapse, patients who did not relapse before death or last visit were treated as 
censored. Statistical inferences for the effects of KIR genes and other covariates on the distribution 
functions of TRM, OS and TTR were summarised using the likelihood ratio tests, the log-rank tests 
and their corresponding p-values.  Cumulative distributions of TRM, OS and TTR over days since 
transplant were estimated by the Kaplan-Meier method for patients stratified by KIR genotype, 
disease and other factors.  For the multiple-event competing risk analysis (supplementary table 2), 
we included relapse, TRM and non-TRM death as competing risks, and considered the marginal 
competing risk models with event time defined to be the “time to first event” (Terry M. Therneau 
and Patricia M. Grambsch, Section 8.4, “Modelling Survival Data, Extending the Cox Model”, 2000, 
Springer-Verlag, New York). These models were selected because of their simple and clinically 
meaningful interpretations. Statistical inferences for the effects of KIR genes and covariates were 
summarised using the likelihood ratio tests and their p-values. The correlation between KIR genes 
was analyzed using Pearson’s correlation coefficient. Analyses were carried out using the S-Plus 8 
(TIBCO Software Inc., Palo Alto, CA) and SPSS (SPSS Inc., Chicago, Illinois) statistical packages. 
Aside from the competing risk model (supplementary table 2.), I performed the statistics myself on 
SPSS with the help and guidance of statistician Dr Colin Woo at the NIH who checked all my 
statistical work.  
For the MRC/NCRI non-transplant AML cohort, I collaborated during the analysis with the trial 
statistician Dr Robert Hills who performed most of the statistical work. This was a necessary part of 
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using the samples from this trial as open access to outcome data was not available to individual 
researchers. I conducted power calculations to estimate the sample sizes required for the effects 
hypothesised using my NIH transplant results (presented in chapter 3) extrapolated to the AML 
population receiving chemotherapy. For analysis of outcome, logistic regression was used, adjusted 
for age, trial and performance status. 
For the prospective cohort of AML patients I performed statistics using SPSS software (SPSS Inc., 
Chicago, Illinois) and Graphpad Prism software (GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com). Normally distributed groups 
were compared using either a paired or unpaired T test as appropriate, as well as a three-way 
ANOVA test when comparing three groups. 
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Chapter 3 KIR genotype in HLA matched allogeneic stem cell transplantation 
3.1 Background 
Although outcomes for allogeneic stem cell transplantation (SCT) are improving, better survival is 
largely related to reduced transplant-related mortality (TRM) and not to reduction in leukaemic 
relapse, which still accounts for about one third of treatment failures.  Relapse represents a failure of 
the conditioning regimen or the alloimmune graft-versus-leukaemia (GVL) effect. Both T-
lymphocytes and natural killer (NK) cells have GVL effects, but the exact mechanism by which 
these two cell types contribute to leukaemia cure after SCT is not known and probably varies 
according to disease type, transplant conditions and donor-recipient match.  
Several studies have drawn attention to the predictive value for relapse and survival of the 
lymphocyte count approximately one month after HLA identical SCT for leukaemia.182-187 A 
previous small series from the NHLBI of 54 patients receiving T-cell depleted allogeneic SCT from 
HLA identical donors, showed that outcome and especially relapse risk, was linked to NK cell and 
not T cell recovery.188 Since NK alloreactivity is determined by mismatches between recipient HLA 
class I group and NK cell killer immunoglobulin-like receptor (KIR) expression,108 patterns of NK-
donor mismatching and KIR genetics in the recipient and donor were examined in order to determine 
whether allo-disparity or specific KIR genotypes were predictive of relapse.  In the multivariate 
analysis, only NK count at day thirty post-transplant emerged as a significant factor affecting 
outcome, but in the univariate analysis, a number of donor KIR factors were significant. In 
particular, donor KIR genes 2DL5A, 2DS1 and 3DS1 (which are highly correlated, i.e. usually 
inherited together), were associated with a significantly reduced relapse rate and improved 
survival.188 Similar results have been reported in recipients of unrelated donor SCT: in a group of 
AML recipients, donors with KIR haplotype B (which includes 2DL5A/2DS1/3DS1) had less relapse 
and more favourable outcome after SCT than recipients of donors without these genes.189 It therefore 
appears that donor KIR genetics may influence the risk of relapse, at least in patients with myeloid 
leukaemia.  
In this study I set out to better define the contribution of KIR genotype to transplant outcome in 
specific disease types by analyzing 261 related donor transplants for leukaemia performed at NIH in 
the fifteen-year period 1993 to 2008. KIR genotype, KIR haplotype and inheritance of genes 2DL5A, 
2DS1 and 3DS1 were included in univariate and multivariate analysis of transplant variables. 
3.2 Hypotheses 
a. Donor KIR genotype is associated with improved outcome after allo-SCT 
b. Donor KIR genotype is associated with robust lymphocyte recovery post allo-SCT  
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3.3 Patterns of donor KIR inheritance 
Firstly I examined the ‘missing KIR ligand’ model,26,28,190 by identifying patients missing an HLA A, 
Bw or C ligand for which their donor had an inhibitory KIR (a situation possible in the HLA 
matched setting due to the fact that HLA and KIR genes segregate separately on different 
chromosomes). I did not evaluate the reverse situation, where donors were missing a ligand for 
patient KIRs as no cases of graft rejection were seen and my focus was the ability of donor NK to 
detect leukaemia cells rather than residual patient immunity against the incoming graft. We then 
assessed the donor KIR genes separately to identify whether individual KIRs are associated with 
differences in outcome measures in univariate analysis. The presence in the donor of three 
favourable KIR genes 2DL5A, 2DS1 and 3DS1 together was then examined. The impact of donor 
haplotype B (defined by the presence of at least one of the genes 2DL5A, 2DS1, 3DS1, 2DS2, 2DS3 
or 2DS5), as well as the total number of activating and inhibitory KIRs,191 were also assessed. 
Definitions 
Donors possessing the three KIR genes: 2DL5A, 2DS1 and 3DS1, (co-inherited with correlation 
coefficients of 0·86-0·96), were termed to have favourable KIRs. Standard patient risk group was 
defined as AML or ALL in 1st complete remission, CML in first chronic phase, and MDS 
intermediate-1 by WHO classification; all other patients were categorised as high risk. Relapse was 
defined as haematological relapse.  
 
3.4 Patient characteristics 
The study comprised 261 consecutive patients receiving HLA identical sibling allografts at the 
NHLBI between 1993 and May 2008. The cohort in which donor samples were available for KIR 
genotyping, encompassed 95% of all HLA sibling transplants in the unit since 1993. Patients 
received conditioning with Cyclophosphamide 120mg/kg and fractionated total body irradiation 
(400-1300cGy) with or without Fludarabine 125 mg /m2 followed by T-cell depleted CD34 cell 
selected SCT and cyclosporin as the single post-transplant prophylaxis for graft-versus-host disease 
(GVHD). Donor samples for KIR DNA typing consisted of 239 cryopreserved donor cell samples 
and 7 buccal swabs. All patients and donors were enrolled onto National Institutes of Health 
treatment protocols and provided written informed consent. Follow up ranged from 6 months to 15 
years. Patient characteristics are described in table 3.1.  
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Table 3.1 Patient characteristics of NIH transplant cohort 
Age Median  36yrs (range 9-66) 
Sex Male 146 (56%) 
 Female   115 (44%) 
Race Asian 35 (13%) 
 African/American 25 (10%) 
 Hispanic  131 (50%) 
 Caucasian 70 (27%) 
Disease  ALL 40 (15%) 
 AML 70 (27%) 
 CML 99 (38%) 
 MDS  39 (15%) 
 CLL/NHL/MM 13 (5%) 
Disease risk group  Standard Risk 105 (40%) 
 High Risk 156 (60%) 
Graft type Bone Marrow 41 (16%) 
 Peripheral Blood Stem 
Cells 
220 (84%) 
CD34+ dose Median   5 x 10 6/kg (range 0·5-16) 
CD3+ dose Median 0.5 x10 5/kg (range 0·005-3) 
Acute GVHD Grade 0-1 107 (57%) 
 Grade 2-4 81 (43%) 
 No GVHD data 72 
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3.5 Results 
3.5-i- Outcome after SCT 
The cohort consisted of 261 patients. The majority of patients (85%) had myeloid diseases, of whom 
seventy (27%) had AML. The outcomes of the 246 for which I had donor samples available were 
representative of the whole cohort of 261 (appendix: supplementary fig. 1). There were significant 
differences between diseases in relapse and OS with the highest relapse rates in AML and ALL 
(table 3.2.)  
Table 3.2 Transplant outcome 
 No pts (%) TRM Overall 
Survival 
Relapse GVHD gd 2-4 
 Disease      
AML  n=70 (27%) 16 (23%) 30 (43%) 24 (34%) 31 (53%) 
MDS n=39 (15%) 6 (16%) 21 (54%) 12 (31%) 4 (36%) 
CML n=99 (38%) 23 (23%) 61 (61%) 21 (21%) 33 (40%) 
CLL/NHL n= 13 (5%) 2 (15%) 6 (46%) 4 (31%) 1 (25%) 
ALL n=40 (15%) 8 (20%) 16 (40%) 17 (43%) 17 (43%) 
Cox model  P= 0.8 P= 0.022* P= 0.03*  P=0.520 
All patients n= 261 55 (21%) 134 (51%) 78 (30%) 85 (44%) 
NB. GVHD data was available in 188 patients.  Cox model used to compare difference in outcomes between diseases. 
Univariate analysis of variables affecting transplant outcome showed that, as expected, high risk 
patients had more relapse, more TRM and lower survival rates (appendix: supplementary table 2). 
CD34 doses above 5 x10 6/kg were associated with less relapse, less TRM and better survival. 
Peripheral blood graft type, higher lymphocyte count at day thirty post transplant (LC30) and later 
transplant era, were all associated with reduced TRM but did not affect survival or relapse rates. The 
only KIR-related variable to affect outcome was the possession by the donor of favourable KIR 
genes 2DL5a, 2DS1, 3DS1 which were associated with reduced relapse and improved OS. No other 
KIR-related variable affected transplant outcome, including missing donor KIR ligand, presence of 
donor haplotype B, total number of inhibitory KIRs and total number of activatory KIRs. 
In multivariate analysis (table 3.3), high risk disease was associated with more relapse, more TRM 
and lower survival rates. Higher LC30 was associated with less TRM (p=0.015) (fig. 3.1a) but did 
not independently affect risk of relapse or OS. Better OS was seen in recipients of a CD34 cell dose 
> 5 x 106/kg.  
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Table 3.3 Multivariate analysis of significant risk factors in Cox models 
 
 
 
 
 
 
 
 
 
 
 
 
3.5-ii-Impact of KIR genes on transplant outcome in multivariate analysis 
KIR gene frequency among the donor population studied was similar to that of published data in the 
normal population.27,192,193 In this sample of 246 patients for whom donor KIR results were available, 
the presence of the three favourable donor KIR genes 2DL5A, 2DS1 and 3DS1 occurred in eighty-
nine cases (35% of donors). In multivariate analysis, patients transplanted from donors with 
favourable KIRs had significantly less relapse (p=0.02) (fig. 3.1b).  
 Hazard Ratio 95% CI P value 
Relapse    
High risk disease  4.65 2.6-8.4 <0.001* 
CD34 > 5 x10 6/kg 0.64 0.4-1.0 0.64 
Donor favourable KIRs 0.54 0.3-0.9 0.02* 
Overall Survival    
High risk disease 3.1 2.0-4.7 <0.001* 
CD34 > 5 x10 6/kg 0.54 0.3-0.8 0.001* 
Donor favourable KIRs 0.64 0.43-0.94 0.024* 
TRM    
High risk disease 2.36 1.3-4.3 0.004* 
CD34 > 5 x10 6/kg 0.55 0.3-1.0 0.057 
PBSC graft 0.68 0.3-1.4 0.276 
LC30 >600 x10 7/l 0.42 0.2-0.9 0.015* 
Recent transplant era 0.95 0.5-1.8 0.866 
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Figure 3.1 Factors affecting SCT outcome in multivariate analysis of 261 patients. a) Lymphocyte count 
at day 30 post SCT and transplant related mortality b) Donor KIR genotype and relapse 
 
3.5-iii-Impact of donor KIR genes in individual diseases 
 
Relapse: Because relapse rates were different in different diseases, I selected factors that 
significantly affected relapse rates in multivariate analysis, and studied them in disease subsets (table 
3.4). The protective effect of favourable donor KIR genes was restricted to patients with AML. AML 
patients receiving transplants from donors with favourable KIRs were four times less likely to 
relapse than recipients of donors not possessing favourable KIRs (p=0.02, Hazard Ratio =0.24) (fig. 
3.2a). 
The protective effect of favourable KIRs on relapse was observed in both standard and high risk 
AML patients (fig. 3.2b). None of 13 patients with standard risk AML receiving SCT from 
favourable KIR donors relapsed, whereas 19 standard risk patients receiving SCT from donors 
without favourable KIRs had a 32% relapse rate. Similarly, patients with high risk AML receiving 
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SCT from favourable KIR donors had a relapse rate of 30%, whereas high risk patient recipients of 
SCT from donors without favourable KIRs had a 70% relapse rate. In diseases other than AML, 
neither favourable KIRs, nor any other KIR-related variable, affected relapse (fig. 3.3), survival, or 
TRM (data not shown).  
Table 3.4 Effect of favourable donor KIR genes on transplant outcome in different diseases 
Patient group  
with donor KIR group 
TRM p HR Survival HR p Relapse HR p 
AML + Fav KIR donor (n=23) 6 (26%) 0.8 1.14 13 (57%) 0.59 0.151 3 (13%) 0.24 0.02* 
Not fav (n=45) 9 (20%)   17 (38%)   20 (57%)   
AML + haplo B donor (n=46) 10 (22%) 0.92 0.95 20 (44%) 1.07 0.86 15 (33%) 0.86 0.73 
Not haplo B donor (n=22) 5 (23%)   10 (46%)   8 (36%)   
MDS + Fav (n=16) 1 (6%) 0.53 0.46 10 (63%) 0.56 0.28 6 (37%) 0.61 0.412 
Not fav (n=17) 2 (12%)   8 (47%)   6 (35%)   
CML + Fav (n=32) 6 (19%) 0.52 0.73 21 (66%) 0.78 0.47 6 (19%) 0.75 0.55 
Not fav (n=63) 15 (24%)   38 (60%)   14 (22%)   
CLL/NHL + Fav (n=4) 0 (0%) 0.56 0.03 3 (75%) 0.01 0.22 0 (0%) 0.02 0.37 
Not fav (n=9) 2 (22%)   3 (33%)   4 (44%)   
ALL + Fav (n=12) 2 (17%) 0.82 0.83 4 (33%) 1.21 0.66 6 (50%)  0.417 
Not fav (n=12) 5 (20%)   11 (44%)   9 (36%)   
High Risk + Fav(n=50) 8 (16%) 0.1 0.51 24 (48%) 0.59 0.02* 19 (38%) 0.63 0.1 
Not Fav (n=94) 25 (27%)   31 (33%)   41 (44%)   
Std Risk Fav (n=37) 7 (19%) 0.43 1.51 27 (73%) 0.88 0.74 2 (5%) 0.27 0.09 
Not Fav (n=65) 8 (12%)   46 (71%)   12 (18%)   
TRM indicates treatment related mortality; HR, hazard ratio; Fav indicates SCT donor with 3 favourable KIR genes 
2DL5A/2DS1/3DS1; Not Fav, SCT donor without all 3 genes; Standard Risk, AML or ALL in 1st complete remission, 
CML in first chronic phase, and MDS intermediate-1 by WHO classification; High Risk = all other patients. 246 patients 
had donor samples available for KIR typing. Bold type with asterix indicates a p value significant at the level of 0.05 or 
below. 
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Figure 3.2 Effect of donor KIR genes on relapse in AML patients (n=68). a) Stratified by donor KIR 
genes b) Stratified by donor KIR genes and risk group 
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Figure 3.3 Actuarial relapse rates for disease subgroups according to donor KIR genotype 
 Transplant Related Mortality: In the entire cohort of 261 patients, LC30 and high risk disease were 
significant for TRM in multivariate analysis. In disease subsets, LC30 below 600 x107/l was again 
significant for TRM in AML (45% vs 9.5% for LC30 > than the median; p 0·04) and MDS (28% vs 
4.8% respectively; p=0·047) but not in CML. In CML, TRM was affected by risk group with high 
risk patients having a higher TRM (39% vs 14%; p=0·005) and by CD34 count with higher TRM for 
CD34 counts below the median (32% vs 12%; p=0·022). In ALL, only bone marrow as the stem cell 
source was a significant risk factor for higher TRM (p=0·043). 
 
Overall Survival: Disease risk, CD34 cell dose and a donor with favourable KIRs significantly 
affected OS in the entire cohort. In disease subsets, disease risk and CD34 cell dose were still 
significant in AML (for risk group: 63% survival for low risk vs 26% for high, p=0·004; for CD34 
dose: 21% below vs 64% above median dose, p 0·001). CD34 dose was also significant for survival 
in CML (28% below vs 79% above median dose).  
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3.6 Discussion 
In this study, I analysed factors affecting allogeneic transplant outcome in a cohort of 261 patients 
with haematological malignancies undergoing T depleted myeloablative SCT from HLA matched 
sibling donors. I identified three donor KIR genes (2DL5A, 2DS1 and 3DS1) associated with a 
reduced AML relapse rate post SCT. My findings suggest that an NK-mediated GVL effect in AML 
may be modulated by specific KIR genes in the donor.  
 
Studying the determinants of allo-SCT outcome can identify risk factors that can be used to optimise 
transplant schedule design and donor selection. Furthermore, clinical results can point to biological 
mechanisms underlying success or failure of allo-SCT. In addition to well recognised disease-related 
factors predicting outcome, my colleagues and others have identified CD34+ cell dose and 
lymphocyte counts thirty days after SCT as predictive factors for transplant outcome.184,194,195 In a 
previous analysis on a smaller cohort of 54 patients, they found that donor KIR genotype was also a 
strong predictor of survival and relapse after SCT. In particular, three closely linked donor genes 
2DL5A, 2DS1 and 3DS1, of the B haplotype were predictive for outcome and relapse.188 I therefore 
extended this observation in the present study where there were sufficient numbers of patients to 
assess the impact of donor KIR group on outcome in different diseases.  Here I show that, in addition 
to known risk factors for outcome (disease risk, disease type, CD34+ cell dose and day thirty 
lymphocyte counts), donor KIR genes 2DL5A, 2DS1 and 3DS1 were associated with significantly 
reduced relapse rates after T depleted SCT. This effect was restricted to patients with de-novo AML 
and had no effect in CML, MDS or lymphoid malignancies.  
 
The impact of donor KIRs on relapse in AML was striking: relapse occurred in 13% of recipients of 
transplants from donors with favourable KIRs and in 57% of recipients whose donors lacked these 
genes (p=0·02). The effect of donor KIRs was seen in both standard and high risk AML: no standard 
risk patient receiving a transplant from a donor with favourable KIRs relapsed compared with a 
relapse rate of 32% for standard risk recipients of donors with unfavourable KIRs. Similarly relapse 
rates for high risk patients were affected by donor KIR group: 30% for recipients with favourable 
KIR donors and 70% for recipients with unfavourable KIR donors.  
 
My results support a recent analysis in AML patients receiving unrelated donor SCT, where SCT 
from donors of the B haplotype (which contains the favourable KIR genes) were associated with less 
relapse.189 There is strong linkage equilibrium among B haplotype genes and it is difficult to be 
certain which genes are associated with the anti-leukemic effect. The statistical problems associated 
with multiple comparisons mean the results must be viewed cautiously. However, in this study, the 
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strongest association with reduced AML relapse was with the KIR genes 2DL5A, 2DS1 and 3DS1 
(p=0.02, HR 0.24) and analysis of B haplotype itself was not found to be significant (p=0.73, HR 
0.86). My findings contrast with data by Hsu et al, who studied the role of donor KIRs in a mixed 
disease population of patients receiving HLA identical sibling, T-cell depleted SCT similar to mine, 
and found no benefit for the presence of any particular donor KIR on outcome.28   Although I found 
that missing a ligand for donor KIRs reduced TRM in AML patients, I could not replicate their 
findings of less relapse and improved survival in these patients. The difference may be explained by 
the fact that patients in Dr Hsu’s study all received bone marrow grafts, whereas the majority of my 
patients received blood derived stem cells. A separate analysis of the thirty nine bone marrow 
recipients in my series did not show any impact of donor KIR groups, while the association between 
donor KIRs and relapse was of greater significance when the PBSCT were analysed separately (p 
<0.029). Further analysis of larger patient series receiving different types of transplant regimens is 
required to clarify these differences.  The disease specificity of my finding, with the impact of KIR 
group genetics mainly affecting AML, is consistent with findings from other centres where NK-KIR 
mediated effects have been found to be strongest in AML,26,28 as well as studies showing that 
alloreactive NK cells do not kill ALL cells in vitro.25  
 
The mechanism whereby KIR genes 2DL5A, 2DS1 and 3DS1 mediate a protective effect against 
relapse is unclear. The previous small study linked these genes to higher NK cell counts post 
transplant suggesting a genetic control of NK cell recovery.188 Interestingly, in my larger sample, I 
did not find an association of these genes with higher lymphocyte counts post transplant, but in the 
small group of patients who did not achieve lymphocyte counts above 0.2 x 109/l, the positive effect 
of these KIR genes was not seen, suggesting that a minimum level of NK cells need to be present for 
the effect of KIR genes to be facilitated. The association between favourable KIRs and lower relapse 
rates was also stronger in PBSCT where higher circulating levels of all cells including NK occur 
earlier after transplant, than with BM grafts. 
  
Since the three favourable genes are usually inherited together, it is impossible to determine whether 
all three, or only one KIR gene acts as a protective factor. Since 1 of the 3 genes occurs in only 5% 
of donors, very large patient cohorts would be required to explore the contribution of specific 
favourable KIR.  
 
These results suggest that there may be specific ligands on the surface of AML cells that make the 
interaction between favourable KIR receptors and AML cells particularly effective at causing NK-
mediated AML-cell death. Alternatively these favourable KIR genes may simply represent a marker 
69 
 
linked to an as yet undefined GVL pathway. Further studies are required to investigate this and 
determine whether the beneficial KIR-AML interaction is restricted to specific AML subtypes and 
reproduced in HLA matched but unrelated SCT.  
 
These findings have practical implications and support the concept of selecting donors by KIR 
genotype in order to optimise GVL effects after SCT for AML. In the absence of a favourable donor, 
patients could be considered for experimental treatments to boost GVL, for example using NK cell 
infusions or lower doses of immunosuppression.  Recent trials using allogeneic NK cell infusions to 
boost immunity post transplant are promising, with small numbers showing that this treatment 
modality is safe and feasible and can lead to reduction in tumour load in some patients.196-198 
Selecting donors with favourable KIRs could potentially increase the ability of such infusions to 
control leukaemia and prevent relapse. This would be a practical possibility since donors with 
favourable KIR genes represent up to 40% of the population. 
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Chapter 4 KIR genotype in AML patients receiving induction chemotherapy  
4.1 Background 
While there are clearly major differences between normal donor NK cells engrafting after transplant 
and the NK cells of a leukaemic patient regenerating after chemotherapy, there are some precedents 
that suggest observations seen in the allograft setting may translate to non-transplant patients. First, 
in both settings, at the time of cellular regeneration, NK cells account for a higher proportion of the 
normal lymphocyte population than normal with a marked increase in both relative and absolute 
numbers of NK cells,195,199,200 suggesting the importance of the NK-mediated immune response in 
both. Second, in both settings, patients who achieve higher absolute lymphocyte counts one month 
after treatment have improved outcome.14,187 Third, there is evidence that patients with greater NK-
mediated cytotoxicity towards leukaemic cells post treatment do better following both SCT and 
chemotherapy.13,26 Gathering further evidence to support the hypothesis that variability in NK cell 
genes may account for variability in disease and relapse risk is an important step forward in 
understanding anti-leukaemia biology and in helping identify those chemotherapy patients who may 
be at higher risk of AML relapse.  If the role of KIR genes is not supported in the autologous setting, 
this information will enable us to re-focus our investigation onto the characteristics of the leukaemic 
blasts in inducing or escaping the humoral or T cell anti-leukaemia control. 
Although we cannot conclude from data in chapter 3 that the improved outcome of transplant for 
AML is a direct consequence of the donor KIR type, the multivariate analysis showing reduced 
relapse in patients receiving transplants from donors with 3 particular KIR genes at least suggests a 
role for donor NK cell activity in this disease. Recent studies to identify risk factors in AML have 
focused on new cytogenetic and molecular markers. This has brought significant advances in our 
ability to stratify treatment intensity according to cytogenetic or molecular risk and enables poor risk 
leukaemias to be selected for stem cell transplant or exploratory treatments while avoiding 
unnecessary toxicity in good risk leukaemias. 
These developments have improved our understanding of AML relapse but focus on identifying 
factors intrinsic to the leukaemia. For example: leukaemic cells which highly express the multi drug 
resistance-1 (MDR-1) gene extrude chemotherapeutic drugs thereby facilitating cell survival;201-204 
mutations of the FMS-like tyrosine kinase 3 (FLT-3) lead to constitutive activation of the tyrosine 
kinase and downstream activation of signalling pathways that mediate cell survival and 
proliferation.205 Less attention has been given to host factors influencing the immune system’s ability 
to prevent the initial occurrence of leukaemia or maintain remission, that is, the competence of the 
immune systems tumour surveillance. The importance of NK cells in killing leukaemic cells is 
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increasingly recognised and further studies into factors which influence an NK cell’s ability to detect 
and destroy a leukaemic target, such as KIRs, are justified. 
The role of KIRs and KIR ligands in predicting disease and outcome for AML has not been 
investigated outside the allogeneic transplant setting. As non-transplant treatments are given to the 
majority of AML patients, it is relevant to explore the role of KIR genetics in these individuals. 
There are indications that KIR-KIR ligand interactions may be important in the setting of autologous 
disease from studies of autologous stem cell transplantation for neuroblastoma,206 lymphoma and 
solid tumours,190 where patients missing a ligand for their inhibitory KIRs had improved survival 
rates. Data in support of an autologous role for KIR-KIR ligands in modifying risk of disease and 
disease outcome has also been produced in the setting of autoimmune and infective disease.114,207 In 
this chapter, I have investigated the role of KIR-KIR ligand interactions in a large cohort of AML 
patients receiving only chemotherapy for their disease. Our normal donors were siblings of US 
patients with haematological malignancies. Their KIR gene frequency was not significantly different 
to the UK donor populations registered at http://www.allelefrequencies.net/kir6002a.asp who are 
demographically matched to the MRC patient cohort. 
4.2 Models for investigating KIR genetics in this study  
The distinct variation in KIR gene inheritance means that NK cells between individuals could have 
differing abilities to identify and interact with leukaemic target cells. Here I investigate whether 
particular KIR genotypes thereby affect (1) predisposition to developing AML and (2) outcome after 
AML chemotherapy. 
4.2-i-KIR gene frequency 
I compared the frequency of KIR genes in individuals with AML and in a normal donor population 
without AML and correlated the presence of individual KIR genes with outcome after AML 
chemotherapy. As discussed in the introduction, although there are 17 different KIR genes which can 
be inherited, some (KIR 2DP1 and 3DP1) are pseudo genes, and do not encode for surface receptors, 
and some (3DL3, 3DP1, 2DL4 and 3DL2) are ‘framework genes’ and inherited by all individuals. I 
therefore restricted my analysis to the 11 KIR genes, which could potentially be of use in predicting 
variation in disease risk and outcome between individuals. 
4.2-ii-Possession of ‘favourable’ and activatory KIRs 
Following the results presented in chapter 3, a primary aim of this study was to investigate whether 
possession of the three ‘favourable’ KIR genes, 2DS1, 3DS1 and 2DL5a also conferred benefit on 
AML patients outside the transplant setting. A recent model from the transplant setting, reported that 
individuals with the more ‘activatory’ haplotype B (containing at least one of the activatory genes 
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KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1)189 had improved outcome 
post SCT. This variable compares those with at least one B haplotype to those with A/A haplotype. 
4.2-iii-Missing a ligand for inhibitory KIRs 
Clinical data from unrelated SCT indicates that patients missing a ligand for their inhibitory KIRs 
have better outcome.26,208 An example of an individual missing a KIR ligand would be a patient 
possessing the gene for KIR2DL2 and/or 2DL3 but missing the C1 ligand for these KIRs by virtue of 
being homozygous for HLA C2. Conversely, individuals possessing KIR2DL1 but being 
homozygous for C1 are missing the C2 ligand for their inhibitory KIR. As all individuals express 
KIR2DL2/3, and most express KIR2DL1, the vast majority of HLA C homozygotes are missing a 
ligand for their inhibitory KIRs. The third ligand in this model is that for KIR3DL1, which 
recognises HLA-B Bw4 molecules with an isoleucine at position 80. Therefore individuals 
possessing this KIR but also homozygous for Bw6 and not possessing any of the HLA A alleles 
which are also recognised by KIR3DL1 (HLA A23, A24, A32) are also missing a KIR ligand. 
4.2-iv-Missing a ligand for activatory KIRs 
A second concept associated with KIR ligands, is that HLA ligands for activatory KIRs are also 
important for educating the NK response. This is of particular interest considering my results in 
chapter 3 linking a combination of largely activatory KIRs with better outcome in AML patients. 
Although strength of binding between most activatory KIRs and HLA class 1 is typically weaker 
than for inhibitory KIRs,209 making it likely that there are other as yet unknown ligands which are 
more specific, this is not the case for 2DS1, where there is good evidence that HLA C2 is indeed its 
main ligand.209-211 NK cells expressing activatory KIR2DS1 from C2 homozygotes are down-
regulated in their cytotoxic ability towards targets whereas in C1 homozygotes they are not.148 This 
suggests a mechanism of tolerance during NK education whereby exposure of activatory KIRs to 
their ligand ‘tunes down’ responsiveness and is complementary to the opposite effect seen when 
inhibitory KIRs interact with their HLA ligand and become ‘licensed’ to kill.  
 If it follows that those missing a ligand for their activatory KIRs do not undergo this ‘tuning down’ 
process, (as seen in the 2DS1+ cells from C1 homozygotes who are missing the 2DS1 ligand C2), the 
model could identify a group as potentially more able to clear leukaemic cells by virtue of their KIR-
KIR ligand genetics. To create this variable, I looked at individuals possessing the activatory 
KIR2DS1 and 2DS2 and assessed whether the corresponding HLA C2 or C1 ligand was present.  
4.2-v-Statistical analysis 
Statistical analysis for this cohort was performed by Dr Robert Hills at Cardiff University in 
collaboration with myself. As stipulated by the MRC trials unit, access to outcome data is not 
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routinely available to individual researchers and working with a designated MRC statistician is part 
of the agreement when accessing samples. The results have been adjusted to take into account factors 
known to affect outcome in this cohort (age and performance status as well as trial). 
4.3 Aims of this chapter 
a. Does a particular KIR genotype predispose to developing AML? 
b. Do individuals with the activatory ‘favourable’ or haplotype B KIR genotypes or those missing a 
ligand for their KIRs have better outcome after chemotherapy for AML? 
4.4 Results  
4.4-i-Patient Characteristics 
I obtained access to a unique cohort of patients from the largest and most comprehensive AML trials 
in the UK. 500 AML patients consecutively enrolled onto NCRI (MRC) AML trials 10 and 15 prior 
to 2006 were included in this study. All patients were aged between 16 and 60 and received four 
courses of intensive chemotherapy, as per protocol. Patients had a minimum follow-up of 3 years, 
incorporating the period at which they are at maximum risk of relapse. Each sample was linked to 
comprehensive cytogenetic, molecular and outcome data collected by the MRC enabling me to ask 
questions about the role of KIRs in AML cytogenetic and molecular subgroups in this project. I have 
KIR genotyping results on 499 patients. One patient aged 9 years was excluded from the analysis. 
4.4-ii-Does a particular KIR genotype predispose to developing AML? 
The KIR gene frequencies of de novo AML did not differ significantly from those of the normal 
population (fig. 4.1). Frequency of KIR2DS2 was significantly lower in secondary AML compared 
to de novo AML and normal controls (26% (10/37) vs. 51% (234/462) for de novo AML, p=0.004 
and 44% (111/246) for normal controls) as were total number of activatory KIR (fig. 4.2 and 4.3). 
There was some evidence that KIR2DL2, which shows linkage disequilibrium with KIR2DS2, was 
also reduced in secondary AML (32% v 54%, p=0.009). Rates of KIR2DS2 and KIR2DL2 were 
lower in both secondary groups: therapy-related AML (t-AML) and those with antecedent 
haematological disorders. Patients with t-AML had lower rates of KIR Haplotype B than those 
without t-AML (27% v 67%, p=0.005).  However, analyses of the AML cohort adjusted for known 
prognostic factors showed no significant prognostic effect of any single KIR group, or KIR B 
haplotype. These results suggest that inheritance of KIR2DS2 may be protective for the development 
of secondary AML and that individuals lacking haplotype B KIR genes are more prone to develop t-
AML. These observations raise the possibility that KIR gene inheritance determines the efficiency of 
immunosurveillance of AML by NK cells in the context of a pre-leukemic disease phase, which 
characterises secondary AML. 
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Figure 4.1 The frequency of KIR genes in the AML population (left) and normal donors (right). There 
is no difference in KIR frequency between the two populations. 
 
 
Figure 4.2 KIR gene prevalence looking at an individual's total number of activatory KIR. Patients 
with secondary AML had less activatory KIR than those with de novo AML or normal healthy controls. 
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Figure 4.3 The frequency of KIR genes in secondary AML compared to a) the normal donor population 
b) de novo AML 
  
b. 
a. 
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4.4-iii-Do individuals with ‘favourable’ or haplotype B KIR genotypes, or those missing a 
ligand for their KIRs have better outcomes after chemotherapy for AML? 
I did not find a favourable effect either for possession of the three favourable KIR genes discussed in 
chapter 3, or for haplotype B in predicting response to AML patients receiving chemotherapy (fig. 4.4 
and 4.5). I did not find that missing a ligand for inhibitory KIRs had any impact in this setting either 
(fig. 4.6). My results combining activatory KIRs and their ligands are more complicated. While 
missing a ligand for activatory KIRs had no statistically significant effect on overall survival in AML 
(p=0.3) there is possibly a trend (fig. 4.7a), and this variable did appear to affect relapse risk with 
individuals missing a ligand for their activatory KIRs having reduced relapse risk compared to those 
not missing a ligand (45% (8/19) for those missing C1 and 41% (19/52) for those missing C2 versus 
56% (110/219) relapse in those not missing a C ligand, p=0.01) (fig.4.7b). These data would suggest 
that individuals missing a C ligand for their activatory KIRs may have greater cytotoxic NK activity 
and therefore supports the model put forward by Fauriat et al148 discussed in section 4.2-iv where it is 
suggested that NK expressing activatory KIRs are tuned down in responsiveness when exposed to 
their HLA C ligand.  
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Figure 4.4 The role of 3 ‘favourable’ KIR on AML outcome in MRC/NCRI trial patients. Presence of 
the 3 'favourable' KIR genes 2DS1, 3DS1, 2DL5a did not affect a) overall survival b) relapse risk in 
AML 
b. 
a. 
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Figure 4.5 The role of KIR haplotype on AML outcome in MRC/NCRI trial patients. Patient KIR 
haplotype did not affect a) overall survival or b) relapse risk in AML. Value 1=patients with haplotype 
B. 
 
a. 
b. 
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Figure 4.6 The role of inhibitory KIR ligands on AML outcome in MRC/NCRI trial patients. Missing a 
ligand for inhibitory KIRs did not affect a) overall survival or b) relapse risk in AML. Value 1= 
patients missing an HLA ligand for their inhibitory KIRs 
  
 
P=0.2 
P=0.2 
a. 
b. 
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Figure 4.7  The role of activatory KIR ligands on AML outcome in MRC/NCRI trial patients. Missing a 
ligand for activatory KIRs a) did not significantly affect overall survival but b) may be associated with 
a reduced relapse risk in AML 
  
P=0.3 
P=0.01 (unadjusted p=0.17) 
a. 
b. 
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4.5 Discussion 
I have shown that the frequency of KIR2DS2 was significantly lower in secondary AML compared 
to de novo AML and normal controls suggesting that inheritance of KIR2DS2 may be protective for 
the development of secondary AML. I have also shown that individuals lacking the activatory 
haplotype B KIR genes are more prone to develop t-AML. Less convincingly, this data also suggests 
that individuals missing a ligand for their activatory KIRs may have a reduced relapse risk after 
AML chemotherapy. These data suggest an important role of activatory KIRs in immunosurveillance 
of AML.  
Does a particular KIR genotype predispose to developing AML? 
The fact that we only see a protective relationship from activatory KIRs in secondary AML and not 
de novo AML is perhaps not surprising. Secondary AML often follows a slow time course starting 
with a dysplastic clone, maybe a few blasts in marrow and proceeding over sometimes many years to 
develop into a full blown leukaemia. During this time, a multitude of genetic and epigenetic changes 
are occurring with oncogenes being switched on and tumour suppressor genes being switched off.212 
It is therefore probable that immune editing would have more capacity to adapt to and control this 
process than a malignant transformation which develops over a matter of weeks, as is often the case 
with de novo AML. Supporting the role of NK-mediated immune editing in protecting against 
secondary AML, higher frequencies of NK cells are found in low risk MDS as compared to high risk 
MDS.212 Also, cytolytic function of NK cells is disrupted in MDS,213 with reduced NK cytotoxicity 
in the RAEB forms at high risk of going on to develop AML214 and increased NK-mediated 
cytotoxicity in low and intermediate risk MDS.215 
Linking an activatory KIR with disease is consistent with data from the infectious diseases setting 
where an activatory KIR genotype limits development of AIDS216 and HCV.217 The role of 
KIR2DS2 as being particularly important has also been identified in the autoimmune setting where 
individuals with KIR2DS2 have an increased risk of developing the diseases rheumatoid arthritis, 
type 1 diabetes and psoriatic arthritis.218-220 
Do individuals with ‘favourable’ or haplotype B KIR genotypes, or those missing a ligand for 
their KIRs have better outcome after chemotherapy for AML? 
I found that the three ‘favourable’ KIRs, haplotype B and missing a ligand for inhibitory KIRs are 
not associated with improved outcome after chemotherapy for AML. However, individuals missing a 
ligand for their activatory KIRs possibly have reduced relapse risk after chemotherapy. The first 
three important negative findings indicate that previous results linking these variables with improved 
outcome in AML after SCT are specific to NK alloresponses and cannot be extrapolated to non-
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allograft treatments. The particular environment that NK cells engraft in after stem cell 
transplantation, the cytokine and chemokine profile and the fact that the regenerating cells belong to 
a different individual, are all factors that differ from the current population, and which could impact 
upon the process of NK-mediated immune surveillance. The finding that missing a ligand for 
activatory KIRs improves outcome is consistent with evidence citing the role of activatory KIRs in 
NK education, where the responsiveness of NK cells expressing activatory KIRs is down regulated 
in the presence of their HLA C ligand.148 My data suggest that in individuals where this educational 
down regulation does not take place (as would be the case in individuals missing that ligand), NK 
cells may be more responsive and therefore better able to recognise and kill leukaemic cells 
emerging during relapse. These data therefore provide important clinical evidence to support for the 
role of activatory KIRs in NK education. It should be noted that throughout this study, the 
statistically significant results I have reported have been adjusted to take into account factors known 
to affect outcome in this cohort (age and performance status as well as trial) and both the adjusted 
and unadjusted p values have been statistically significant. For the result linking individuals missing 
a ligand for their activatory KIRs with reduced relapse risk after chemotherapy, only the adjusted p 
value is significant (0.01) while the unadjusted value is 0.17. This result should be interpreted with 
caution since there is a possibility that age and performance status may influence the activatory NK 
response to leukaemia. These factors could account for the discrepancy, since older, frailer patients 
are more likely to have aggressive disease, and be less susceptible to the effects of 
immunosurveillance. Further analysis of this variable, stratifying according to age, performance 
status and cytogenetic risk group in a larger cohort would be necessary to address this limitation. 
A general concern of studies testing prediction of disease risk and outcome by presence or absence of 
a gene is that genetic analysis does not account for variations in expression of the protein coded for 
by the gene. Overall, KIR gene expression correlates well with RNA transcription,221 and as previous 
studies had shown KIR to exhibit 94% sequence homology, 222 genotype-phenotype discrepancy was 
not initially thought to be a large problem with KIR genes. However, rare alleles of KIR3DL1 have 
been shown to be expressed at a lower level than others.223,224 There are also allelic variants of other 
KIRs which lead to sequestration of the receptor in the cell cytoplasm225 or secretion of the receptor 
from the surface.226 My study is thus limited by the fact that the genotyping method used was not 
sensitive enough to detect these alleles. These non-expressed alleles are however rare. The 
commonest non-expressed allele is KIR2DL4 but as my genotyping method enabled identification of 
the null allele and KIR2DL4 is not one which is incorporated into any of the missing ligand models 
(as its ligand is, as yet unknown), this should not affect the conclusions of this study. Genotype of 
activatory KIRs correlates well with phenotype and most activating KIR loci encode a single 
frequent allele.227,228  
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A further concern with KIR genotyping studies is the effect of multiple testing on the statistical 
significance of results, that is, the risk of a false positive finding increases with the number of 
variables incorporated in the model. If enough variables in a data set are explored without a prior 
hypothesis, a positive answer from one can occur due to chance alone. For this reason, it was decided 
we could not analyze the data to ask the question: is the effect of KIR genes mediated by cytogenetic 
subgroups?  This is unfortunate as cytogenetic stratification would be interesting, cytogenetics 
having been shown to impact greatly on AML outcome and it being biologically plausible that 
immune effects such as KIR profile may be not have a chance to take effect in the aggressive disease 
typically seen in individuals with poor cytogenetics. Not separating these individuals from the rest of 
the cohort may have therefore masked a possible effect. Selected analysis of this question may be 
possible in the future. 
To account for multiple testing, in collaboration with the NCRI MRC statistician, I restricted 
statistical significance at the 0.01 level rather than the usual 0.05.  Nevertheless, the findings in 
secondary AML make a further study with a larger cohort of secondary AML patients worthwhile. 
An important group to look at are patients with previous haematological malignancies such as 
Hodgkins and non Hodgkins lymphoma, Myeloma and Waldenstrom’s macroglobulinaemia as these 
patients have a relatively high risk of developing AML following their treatments. If we find that 
these patients segregate to the poor risk KIR genotypes (low numbers of activatory KIRs/negative for 
KIR2DS2/negative for KIR haplotype B), those deemed higher risk could be counseled 
appropriately, screened more regularly, and perhaps have it built it into their initial treatment 
algorithm to be particularly careful with alkylating agents etc.  
It would also be interesting to study MDS patients to determine whether KIR 2DS2 is under 
represented in those who progress rapidly to AML. Such data could improve the predictive power of 
the IPSS score. Individuals at high risk of early progression could be selected for earlier therapeutic 
interventions and SCT while a watch a wait strategy could be safely adopted in lower risk patients.  
How might activatory KIRs reduce the risk of secondary AML? As discussed in the introduction, 
when NK cells activatory KIRs bind a ligand on a target cell, this triggers NK-mediated killing of 
that target cell provided the activatory signal is not inhibited by inhibitory receptor signaling. It 
therefore follows that individuals with a greater number of activatory KIRs are perhaps better 
equipped for this process. One interesting possibility is that KIR 2DS2 has a particular binding 
affinity for an, as yet unknown, ligand expressed on AML blasts.  While 2DS2 can bind HLA C1 
molecules on target cells, the binding affinity for the interaction between activatory KIRs is much 
lower than that for their inhibitory.229 This raises the possibility that this receptor has evolved to bind 
to an alternative target. Further studies are required to identify 2DS2-binding ligands on AML blasts. 
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A further possibility is that the effect of activatory KIRs on immune editing is mediated via T cells, 
the NK cells acting in a co stimulatory role and making T cells more sensitive to small quantities of 
antigen.230 
In terms of practical applications of these data, identifying a genetic basis, which may influence 
immune editing of AML, is an important step forward in our understanding of the immune response 
to the disease. Results from genetic studies can provide an invaluable tool for directing future 
biological studies.  
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Chapter 5 Phenotypic changes in surface receptors and cytotoxic function of NK 
cells in AML 
The observation that numbers of NK cells are increased in AML at presentation174,200,231 suggests that 
NK cells are part of the immune response to leukaemia. However, it is unclear whether these NK 
cells are functionally competent to recognise and kill their leukaemic targets. Indeed it is possible 
that NK cells from AML patients are functionally defective because of unfavourable immune editing 
of the immune system by the leukaemia (a process explained in section 1.9.)   
In this chapter I describe my attempts to characterise NK phenotype and function in AML and to 
answer the question whether NK cells in AML patients are normal or defective. As detailed in 
chapter 2, I have prospectively collected cell samples and outcome data on a cohort of 32 AML 
patients sequentially presenting at the Hammersmith Hospital in London during the period of my 
PhD to provide the samples for this work. 
5.1 Background 
With the exception of some studies on activatory receptors in AML,174,231 little has been published on 
NK cell surface receptors in this context.  As discussed in my introduction, it is clear that surface NK 
receptors are critical for recognition and killing of malignant target cells. It is also known that the 
percentage expression of receptors vary between individuals89 and that expression density of certain 
activatory NK receptors correlates with cytotoxic ability.91,232 That AML blasts may affect NK 
surface receptor phenotype has been shown, where the number of certain activatory receptors was 
reduced in AML patients.174 However, these studies tend to focus on one or two receptors and/or 
single aspects of NK cytotoxicity and a comprehensive characterization of NK phenotype and 
function in AML has yet to be performed. 
The main receptors used by NK cells to identify target cells are the C-type lectin receptors, KIRs and 
NCR. Cytotoxic function occurs via three main mechanisms: perforin/granzyme release, cytokine 
production and death receptor pathways. In this chapter I measure NK phenotype and function by 
comparing AML patients with normal controls. The functional ability of CD56 bright NK cells 
differs to that of CD56 dim with the latter being more efficient at cytotoxic killing. Recent work has 
shown that the balance of CD56 bright and dim cells can be altered in disease states such as HIV and 
after stem cell transplantation. 233,234 The CD56 bright/dim ratio is also associated with alteration in 
NK functional ability in the post transplant period.235 I therefore include an assessment of CD56 
surface expression to assess the role of this factor in AML patients receiving chemotherapy. 
After characterising NK cell surface receptor expression, I investigated the cytotoxicity of all NK 
cells, defined as CD56+, CD3- cells. Then, in view of my results from chapters 3 and 4 indicating an 
86 
 
impact of KIR genes on NK-mediated cytotoxicity towards AML cells, I extended my investigation 
to see whether KIR expression affects the cytotoxicity of NK cells. It has been shown in the setting 
of HIV, that NK cells expressing particular KIRs show enhanced NK cytotoxicity.236,237 Expression 
of particular KIRs also affects the ability of NK cells to achieve full maturity depending on the KIR-
ligand setting in which they develop (detailed in section 1.8).145-147  
I also assessed the important NK receptor ligands on the blast cells of patients to see whether any 
changes in NK phenotype were related to disease-specific factors on the AML blasts. This also 
enabled me to look for evidence of immune escape where blasts could adapt their phenotype to evade 
immune responses.  
5.2 Aims of this chapter 
1. Is NK surface receptor phenotype in AML different from that of healthy individuals?  
2. Do any surface receptor abnormalities seen in AML normalise in remission?	  
3. Is NK cell cytotoxicity abnormal in AML patients?	  
a. Cytotoxic abnormalities in all NK cells 
b. Are cytotoxic abnormalities in NK cells specific to cells expressing particular KIRs?  
c. Do cytotoxic abnormalities in NK cells affect all triggering mechanisms or are they restricted to 
cytotoxicity triggered by cell contact? 
d. Do KIR ligands affect the cytotoxicity of NK cells? 
4. Do any cytotoxic abnormalities seen in AML normalise in remission? 
5. What is the repertoire of NK ligands on AML blasts? 	  
6. Is expression of NK ligands on leukaemic blasts associated with changes in NK receptor 
phenotype or function? 	  
7. Do individuals with abnormal phenotype have worse cytotoxic function? 
8. Is it possible to induce abnormalities by exposing normal NK cells to AML blasts?  
 
 
5.3 Results 
After patient characteristics, results are organised as to address the aims in section 5.2. 
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Patient characteristics 
Patient samples (n=32) were collected prospectively from the Hammersmith Hospital and compared 
with remission samples on those same patients where available (n=12) and with healthy control 
individuals who were matched closely for age and sex (n=15). AML patients who were eligible for 
therapy were treated with the standard UK first line chemotherapy treatment of Daunorubicin (50-
60mg/m2 x3 doses over 5 days) and Cytarabine (100mg/m2 x 20 doses over 10 days). Samples from 
patients who achieved remission after this were taken when their blood counts recovered and before 
subsequent chemotherapy was started. In some patients, further remission samples were taken after 
subsequent treatment courses and at longer time points as detailed. Patients received standard 
supportive care with antifungal, anti viral and antibiotic therapy as appropriate. Patient 
characteristics are detailed in table 5.1. 
Table 5.1 AML patient characteristics 
 No. (%) 
No. patients 32 
Median age in years (range) 61 (21-87) 
Sex ratio (M:F) 1.7:1 
Cytogenetics  
    Good risk 3   (10%) 
    Intermediate risk 17 (57%) 
    Poor risk 10 (33%) 
    Unknown/insufficient sample 2 
Primary AML 16 (50%) 
   Secondary to MDS/MPD 14 (44%) 
   Secondary to previous therapy 2   (6%) 
Presenting WBC (x109/L)  
   Raised (>11) 14 (44%)(median 50, range 16.1-126) 
   Normal (4-11) 3   (9%) 
   Cytopaenic (<4) 15 (47%) 
Response to first line treatment (DA 3+10)  
   Complete remission 14 (45%) 
   Induction failure/partial remission/not given 17 (55%) 
   Unknown (patient refused Rx and left UK) 1 
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5.3-i- Is the NK surface receptor phenotype in AML different from that of healthy individuals?  
Comparing NK surface receptor phenotype in AML with that of healthy controls (fig. 5.1 and 5.2), I 
found an increase in NK cells expressing the inhibitory receptor NKG2A (p=0.0463, fig. 5.2d) and a 
reduction in the expression of the activatory receptor NKp46 (p=0.0068, fig. 5.2c). There was no 
difference in surface expression of CD56, NKG2D, KIRs, NKp30 or NKp44 on NK cells in AML 
patients compared to normal controls (fig. 5.2a-d).  
 
Figure 5.1 Examples of histograms showing NK surface phenotype in a representative AML patient and 
healthy control. Open histograms represent isotype-matched monoclonal antibody staining. Filled 
histograms represent staining with specific PE-congugated monoclonal antibodies 
  
5.3-ii-Do any surface receptor abnormalities seen in AML normalise in remission? 
Having found an abnormality in the balance between inhibitory and activatory surface receptors, I 
examined whether these changes normalised when patients were in remission after chemotherapy 
(fig. 5.3). The increased NKG2A expression seen in AML patients at presentation did not, in fact it 
continued to increase (p=0.008) in all but 3 patients whereas the reduced NKp46 expression seen at 
AML presentation, normalised in remission (p=0.01).   
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    e.
 
Figure 5.2 NK receptor expression in AML patients compared to normal controls. a) Proportions of 
CD56 bright and dim NK cells were not different between the groups b) There was no difference in 
surface expression of KIRs c) NKp46 expression was lower in AML but NKp30 and NKp44 were not 
different to normal controls d) AML patients showed an increase in NK expressing the inhibitory 
receptor NKG2A but no difference in NKG2D expression e) Gating strategy to identify NK from PBMC 
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Figure 5.3 NK phenotypic abnormalities in AML were partially restored in remission. (a) NKp46 
expression was restored to normal levels (b) NKG2A expression remained elevated. P values denote 
significance of paired T tests comparing AML T1 with remission and unpaired T tests comparing AML 
with healthy controls. Horizontal bars denote mean expression. (c) NKp46 and NKG2A expression in a 
representative healthy control (left column) and AML patient at serial time points (right column): 
diagnosis (T0), following induction chemotherapy (T1), following consolidation chemotherapy #1 (T2), 
and following consolidation chemotherapy #2 (T3). Abbreviations: HC: healthy control 
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I then examined all receptors, even those without a statistically significant abnormality in AML, to 
see whether any changes occurred in patients after chemotherapy. NKG2D expression was 
unchanged in remission (fig. 5.4a). Expression of KIR2DS1/L1 and 2DS2/L2 were unchanged in 
AML patients at remission compared to presentation although KIR3DL1 was down regulated in 
remission samples (fig. 5.4b). There was a statistically significant up regulation of NKp30 (p=0.02). 
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Figure 5.4 Expression at presentation and remission of NK receptors whose expression was not 
significantly altered at AML presentation a) NKG2D expression was unchanged in remission b) 
Expression of KIR2DL1/S1 and 2DL2/S2 were unchanged in remission. KIR3DL1/S1 was reduced c) 
NCRs tended to increase in AML remission compared to presentation (paired t tests). 
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5.3-iii- Is NK cell cytotoxicity abnormal in AML patients? 
 
a. Cytotoxic abnormalities in all NK cells 
Looking at the cytotoxicity of all CD56+, CD3- NK cells, there was strikingly reduced 107a 
(p=0.0002), TNFα (p=0.008) and IFNγ (p=<0.0001) production in AML patients towards leukaemia 
target cells (K562) compared to the NK cells of normal controls (fig. 5.5a). Fas ligand cytotoxicity 
was normal. When NK cell-mediated cytotoxicity in AML patients towards their own AML blasts 
was measured, cytotoxicity was as low, or lower than towards the K562 leukaemia cell line (fig. 
5.5b). 
 
 
Figure 5.5 NK cytotoxicity and effector function in AML patients at diagnosis compared to healthy 
controls a) Total NK (CD56+, CD3-) cytotoxicity (CD107a degranulation), TNFα and IFNγ production 
and Fas ligand expression against K562 leukaemia targets in 32 patients with AML and 15 healthy 
controls. Cytotoxicity towards K562 was significantly reduced in AML patients compared to normal 
controls in all measures except Fas ligand b) NK response at AML presentation to autologous blasts 
was as defective or more defective than towards K562 cells in all measures except Fas ligand. 
Horizontal bars denote mean expression. Abbreviations: NC: healthy control, AML: acute myeloid 
leukaemia (unpaired t tests). 
 
 
 
  
93 
 
b. Are cytotoxic abnormalities restricted to NK cells expressing particular KIRs?  
Cytotoxicity of KIR+ NK cells (fig. 5.6a) and KIR- NK cells (fig. 5.6b) towards leukaemic cells was 
significantly reduced in AML patients compared to normal controls. There was no difference 
between one particular KIR positive NK clone and another. The defect is seen in NK cells expressing 
all the different KIR receptors assessed. There was however, more cytotoxicity from KIR positive 
cells than from KIR negative cells. 
 
 
Figure 5.6 KIR specific NK cytotoxicity and effector cytokine production in AML patients at diagnosis 
compared to healthy controls. a) comparison of NK cytotoxicity and effector cytokine function in KIR+ 
subsets; b) comparison of NK cytotoxicity and effector cytokine function in KIR- subsets. Figures show 
greater cytotoxicity and effector cytokine production from healthy control NK than AML patient NK 
cells and from KIR+ than KIR- NK cells irrespective of which particular KIR is expressed. Horizontal 
bars denote mean within group. Abbreviations: HC: healthy control, AML: acute myeloid leukaemia 
(unpaired t tests). 
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c. Do cytotoxic abnormalities in NK cells affect all triggering mechanisms or are they restricted 
to cytotoxicity triggered by cell contact? 
NK cells from AML patients stimulated with PMA and Ionomycin maintained their ability to 
degranulate and produce TNFα and IFNγ (fig 5.7). This is in marked contrast to the results in figures 
5.5 and 5.6 showing AML patients having reduced NK function after stimulation with leukaemic 
cells. This indicates that the defect in AML is specific to NK stimulation by cell contact and that the 
abnormality is not a structural one of the NK cell itself but rather in its ability to be stimulated by 
leukaemic cells to kill. 
 
Figure 5.7 NK cells stimulated with PMA/Ionomycin maintain normal function in AML patients. NK 
cytotoxicity (CD107a degranulation), TNFα and IFNγ production in AML patients at diagnosis (T0), 
remission (CR) and healthy controls (HC) following stimulation with PMA/Ionomycin. Horizontal bars 
denote mean expression. Error bars denote standard deviation between individuals within group. Three 
groups compared using one way ANOVA tests. Abreviations: HC, healthy control; T0, AML 
presentation; CR, complete remission. 
 
d. Do KIR ligands affect the cytotoxicity of NK cells? 
In view of a number of pre-clinical studies indicating that exposure to KIR ligands (in particular 
HLA A, B and C) is important for NK education both in facilitating cytotoxic function and in 
maintaining tolerance (see section 1.8), as well as clinical studies in SCT suggesting that differential 
NK-mediated GVL depends on inherited KIR-KIR ligand variability,26,28,148 I investigated whether I 
could find correlates to this work in clinical samples from patients. In case any effect of KIR ligands 
on cytotoxicity was something specific to NK undergoing immune editing by AML blasts, I also 
looked in normal control and remission samples. I did not find any differences in cytotoxicity 
between individuals with different KIR-KIR ligand profiles either for inhibitory (fig. 5.8) or 
activatory (fig. 5.9) KIRs. 
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Figure 5.8 The role of inhibitory KIR ligands on NK cell (CD56+, CD3-) cytotoxicity towards K562 
leukaemic target cells after 5 hour incubation. In each graph unpaired t tests compared those with a 
ligand for their inhibitory KIR (KIR2DL1+ C2+, first column; KIR2DL2/3+ C1+, second column, 
3DL1+ Bw4+, third column) and those without in three groups: from left, healthy donors (NC), AML at 
presentation (AML) and AML at remission (AML R). Columns represent from left to right: 
degranulation, TNFα and IFN γ production. There was no beneficial effect of a) Missing a particular 
HLA ligand for inhibitory KIR or b) missing any HLA ligand for inhibitory KIRs on NK function. 
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Figure 5.9 The role of activatory KIRs on NK cell (CD56+, CD3-) cytotoxicity towards K562 leukaemic 
target cells after 5 hour incubation. In each graph unpaired t tests compared those with a ligand for 
their activatory KIR (KIR2DS1+ C2+ or KIR2DS2+ C1+) and those without in three groups: from left, 
healthy donors (NC), AML at presentation (AML) and AML at remission (AML R). Possessing a ligand 
for a) 2DS1 or b) 2DS2 does not affect NK cytotoxicity or effector cytokine production in any group. 
Columns represent from left to right: degranulation, TNFα and IFN γ production. 
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5.3-iv-Do any cytotoxic abnormalities seen in AML normalise in remission? 
The reduced NK cytotoxicity towards leukaemia cells in AML partially normalised in remission (fig. 
5.10a). Degranulation function was restored and IFNγ production was partially restored. Patients 
who achieved remission were a subset who did not have abnormal TNFα production at diagnosis 
suggesting that this could be used to predict response to treatment (as further discussed in chapter 6.) 
Aside from a few individuals, there was no restoration of cytotoxic function towards autologous 
blasts after the first course of chemotherapy (fig. 5.10b). 
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Figure 5.10 Partial normalisation of NK cytotoxic abnormalities in AML remission a) There was 
normalisation of degranulation and partial normalisation of IFNγ production but not TNFα towards 
K562 leukaemia cells. Paired t tests comparing D0 with remission, unpaired t tests comparing remission 
with healthy controls b) Aside from a few individuals, there was generally no improvement in 
cytotoxicity towards autologous blasts (paired t tests). Abbreviations: D0, AML presentation; CR, 
complete remission; NC, healthy controls 
 
  
98 
 
5.3-v-What is the repertoire of NK ligands on AML blasts?  
Figure 5.11 shows that DR4/5 (the ligands for TRAIL), Fas (which binds Fas Ligand) and HLA E 
(the ligand for NKG2A), had a range of expression in different AML patients, with high levels on the 
blasts of some individuals and low or no expression on the blasts of others. All blasts expressed class 
1 HLA molecules (HLA A, B, C-the ligands for KIR receptors) and these were not down regulated in 
these AML patients, in fact all blasts analysed had extremely high expression of HLA class 1. 
MICA/B (the ligands for NKG2D) expression however, was low or absent in most of the patients.  
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Figure 5.11 Expression of NK receptor ligands on the AML blasts of 32 patients. X axes represent the 
ligand of interest. Y axis represents percentage of AML blasts expressing that ligand. 
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5.3-vi-Is expression of NK ligands on leukaemic blasts associated with changes in NK receptor 
phenotype or function?  
NKG2A and its ligand HLA E  
Although I show above that NKG2A is significantly upregulated in AML (fig. 5.2d), it is clear that a 
subset of AML patients did not have high NKG2A levels (circled in red below, fig. 5.12a): their 
NKG2A expression appeared lower than normal controls. While this may just be normal variation, I 
thought it would be interesting to look at whether expression of HLA E, the ligand for NKG2A, 
influences expression of the receptor. I hypothesised that low HLA E expression on AML blasts may 
explain a low NKG2A expression, and that those individuals with high HLA expressing blasts may 
elicit a high NKG2A expression in response. What graphs 5.12b show, is that the opposite may be 
true. In patients who express low levels of HLA E on their blasts, NKG2A expression is high and in 
patients with high HLA E expression, NKG2A expression is low. In view of this pattern, I looked to 
see whether a ratio of HLA E to NKG2A at presentation could provide an informative predictor of 
NK cytotoxicity in AML patients but found no relationship with cytotoxicity (fig. 5.12c). 
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Figure 5.12 Relationship between NKG2A expression and that of its ligand HLA E in AML a) While 
most had a raised proportion of NKG2A expressing NK cells, a subset of AML patients had low 
NKG2A (red circle) b) Low NKG2A expression was associated with high HLA E expression on blasts, 
although this correlation did not quite reach statistical significance c) HLA E/NKG2A ratio did not 
predict NK cytotoxicity. 
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5.3-vii-Do individuals with abnormal phenotype have worse cytotoxic function? 
Different abnormalities in NK surface receptor phenotype were associated with different 
abnormalities in cytotoxic function: high NKG2A was associated with reduced TNFα production 
(fig. 5.13a) and low NKp46 expression with reduced degranulation and IFNγ production (fig. 5.13b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 The effects of abnormal NK surface phenotype on NK cytotoxicity and effector cytokine 
production. Individuals were separated into those with receptor levels above and below the median. 
Unpaired t tests compared the two groups a) High numbers of NK expressing surface NKG2A were 
associated with reduced TNFα b) Low NKp46 was associated with reduced CD107a and IFNγ 
production 
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5.3-viii-Is it possible to induce abnormalities by exposing normal NK cells to AML blasts?  
To test the effect of AML on NKp46 and NKG2A expression, ex-vivo selected NK cells from 
healthy controls were co-incubated with primary AML blasts from patients at a 10:1 ratio for 24 
hours and their phenotype assessed in 4 independent experiments. There was no significant 
difference in the expression of NKG2A and NKp46 in control NK cells after co-culture with 
leukaemia cells + IL-2 (200 iU/mL) compared to NK cells incubated for 24 hours in the absence of 
AML blasts + IL-2 (200 iU/mL)(data not shown).  The effect of AML blasts on cytotoxicity and 
effector function of peripheral blood NK cells from 3 healthy controls was then tested. After 24 
hours co-culture of NK cells with primary AML blasts (ratio 10:1) + IL-2 (200 iU/mL), the NK 
effector function was assessed against K562 leukaemia targets (ratio 1:1). Co-incubation resulted in 
significant impairment of NK cytotoxicity and effector function with marked reduction in TNFα 
production (p=0.02), IFNγ production (p=0.01) and a trend to reduced CD107a degranulation 
(p=0.07) against K562 leukaemia targets (fig. 5.14). Experiments performed without Il-2 resulted in 
poorer NK cell yield after incubation but a similar pattern of NK inhibition to that seen in cells 
cultured with Il-2. Using NK from the same healthy individual I assessed the effect of cells from two 
different AML patients on the function of healthy NKs and found that both inhibited cytotoxicity 
(fig. 5.15). 
 
 
Figure 5.14 AML cells induce impairments in NK effector function in vitro. The reduction in healthy 
donor NK CD107a degranulation, TNFα and IFNγ production against K562 leukaemia target after 24 
hours of co-culture with primary AML blasts (ratio of 10:1) + IL-2 (200 iU/mL), is presented.  The 
results are expressed as a normalised ratio against healthy donor NK.  
103 
 
NK+IL2
NK+IL2 + 
blasts from 
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CD56+ CD3- CD56+ CD3- CD56+ CD3-
54.6% 18.3% 25.7%
42.7% 11.8% 13.4%
23.3% 11.4% 17.3%
 
Figure 5.15 Representative FACS plots showing the effect of co-incubating AML blasts from 2 different 
patients on healthy donor NK cell cytotoxicity and effector function are presented. After 24 hours of 
healthy donor NK co-culture with primary AML blasts (ratio of 10:1) + IL-2 (200 iU/mL), the effector 
function of NK cells was assessed against K562 leukaemia targets (ratio 1:1). Plots are gated on 
CD56+CD3- NK cells. 
 
Summary of results 
In section 5.3 I showed that in AML patients, the NK receptor surface phenotype was different to 
that of normal individuals. There were greater numbers of cells expressing the inhibitory receptor 
NKG2A and lower expression of the activatory receptor NKp46. This abnormality creates an 
imbalance in the circulating NK cell population in AML, with cells more predisposed to inhibit 
cytotoxicity than to activate. I then showed that NK cytotoxicity towards leukaemic cells was 
reduced in AML patients compared to normal controls and that this reduction affected both 
degranulation and production of cytokines TNFα and IFNγ but was not specific to KIR-expressing 
NK cells. The abnormal cytotoxic function in AML only occurred when NK were stimulated by 
contact with leukaemic target cells, the ability of AML NK to be activated by other stimulants 
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(PMA/Ionomycin) remained intact. I then show that there is partial restoration of NK phenotype and 
function in AML patients who achieve remission. Finally, I show that the abnormalities seen in AML 
patients are inducible in the NK of healthy donors after incubation with AML blasts, suggesting that 
the AML ‘edits’ the immune system by impairing the ability of NK cells to recognise and kill 
enabling it to evade the host immune response.   
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5.4 Discussion 
In this chapter, I showed in a prospectively collected cohort of 32 AML patients that NK cells of 
AML patients have an abnormal surface phenotype and reduced cytotoxic function. I found evidence 
for immune editing of NK cells in AML with a shift in the balance of NK surface receptors away 
from NK activation towards NK inhibition and a reduced ability to degranulate and produce 
cytokines. My findings suggest a dysfunction in NK-mediated immune surveillance in AML and 
identify specific areas of NK dysfunction, which could be targeted by future therapeutic 
interventions. I showed that while some of these changes normalised in remission, some did not, 
possibly explaining the high risk of relapse post chemotherapy and why adoptive immunotherapy of 
autologous NK cells in AML has had limited treatment benefits. The discussion of my results is 
structured around my aims for this chapter. 
 
Is the NK surface receptor phenotype in AML different to that of healthy individuals?  
My finding that numbers of NK expressing the inhibitory receptor NKG2A was raised and 
expression of the activatory receptor NKp46 was reduced in AML patients compared to normal 
individuals provides evidence in support of the hypothesis that AML blasts can potentially edit the 
immune system to avoid elimination by NK cells. A raised NKG2A level has also been seen in 
hepatitis C (HCV) infection238,239 where it is associated with reduced cytotoxic killing of infected 
cells239 suggesting that a similar process may occur in infective disease. Further support of our 
observation that NKG2A levels are important for regulating immune responses comes from 
experiments in patients with psoriasis, an autoimmune disease, where low NKG2A levels occur.240   
My finding of NKp46 down regulation in AML is supported by work from Costello et al, showing a 
reduction in NKp46 expression in AML patients.174,231 Our results do however, differ in that they 
also found a reduction in NKp30 and no change in NKG2A. One possible reason for this discrepancy 
is that they used different methods for gating NK cells. While we excluded blasts with a separate 
gate (CD13, 33, 34) and then identified CD56+, CD3- cells to phenotype, they excluded blasts using 
low expression of CD45 without other steps to remove any blasts which may be CD45 high or 
considering NK cells which may be CD45 low. It is possible therefore that Costello’s NK cell 
population differed significantly to ours.  They also excluded all patients with blast counts over 50 
because they found it difficult to separate the NK population from these samples. It is therefore also 
possible that these excluded patients may explain why our results are different. In our cohort, 16% of 
AML patients (5/32) had blast counts >50 x 109/L.  
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Do any surface receptor abnormalities seen in AML normalise in remission? 
The partial restoration of normal NK phenotype in AML remission where NKp46 normalises but 
NKG2A continues to climb has also been seen in melanoma patients post chemotherapy241 and on 
clearing the HCV virus.239 The normalization of surface receptors might be expected when NK are 
no longer exposed to AML blasts; however, it is unclear why NKG2A continues to rise. It is possible 
that this increase could be secondary to chemotherapy. AML chemotherapy interferes with 
regenerating bone marrow stromal cells242 which enable NK cells to develop a mature phenotype.243 
Chemotherapy may also interfere with dendritic cells, which are important for normal NK cytotoxic 
function.244 High NKG2A levels are seen after ATG induction treatment for kidney transplant245 
where they normalise after a year. It has also been shown that in cytotoxic T cells, Il-15, TGFβ and 
Il-12 are associated with up regulation of NKG2A in vitro246-248 suggesting that chemotherapy-
induced changes in the cytokine milieu might explain continuing abnormalities in NK surface 
receptors.  Also, after SCT, high Il-15 levels are associated with higher activatory receptors249 and Il-
15 can be used in vitro to induce this in cells from AML patients,250 suggesting that it may be 
possible to use Il-15 therapeutically to reverse some of the changes we found in NK cells. 
 
Is NK cell cytotoxicity abnormal in AML patients? 
AML NK cells degranulated significantly less (p=0.0002), and produced significantly less TNFα 
(p=0.008) and IFNγ (p=<0.0001) in response to leukaemia target cells compared to NK cells from 
healthy volunteers. This further supports the notion that AML blasts increase their chances of 
survival by altering or ‘immunoediting’ the NK response. The finding that KIR-expressing cells 
exhibited more cytotoxicity and cytokine production than KIR-negative NK cells supports my 
conclusion in chapters 3 and 4 that KIRs play a role in shaping the immune response to leukaemia. 
However, the fact that this effect was seen with all KIR-expressing cells with no difference found 
between cells expressing one type of KIR from cells expressing another, means we did not 
demonstrate a mechanism for why particular KIR genes such as 2DS2 may be beneficial. One 
limitation of my method, which may explain this, is that KIR antibodies cannot as yet distinguish 
between activatory and inhibitory KIRs. Therefore an increased cytotoxicity from activatory KIR-
expressing NK cells, could have been masked by the fact that cytotoxicity from inhibitory KIR-
expressing cells was measured with them. It will be interesting to repeat these experiments when 
further developments in biotechnology allow us to better differentiate the two. Of course, a further 
possibility is that, as a range of receptor-ligand interactions as well as chemokines and cytokines play 
a role in triggering cytotoxicity on target cell recognition251 it may be that although KIR+ cells are 
more cytotoxic than KIR- ones, KIRs are not the primary factor in this process. 
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A possible mechanism by which AML may induce abnormal NK-mediated cytotoxicity, is abnormal 
expression of the immunosuppressive tyrosine-converting enzyme Indoleamine 2, 3-dioxygenase 
(IDO). This has been suggested as a mechanism for reduced NK cytotoxicity in melanoma 
patients.252 Abnormal IDO expression also influences T cell function in AML patients.155 In view of 
these data, I looked to see if this was the case for NK cells in AML. I identified which of my cohort 
were IDO positive and which negative by RT PCR using cDNA extracted from my samples. 
However, I did not find a difference in NK cell function between NK pre-incubated with IDO 
positive and IDO negative blasts (data not shown). Although further experiments would be needed to 
confirm, it does suggest that IDO is not important for NK function in AML.  I also looked to see 
whether down-regulation of transcription factors such as eomesodermin in NK cells exposed to AML 
blasts may explain our findings in view of data from a murine AML model suggesting that this 
mechanism is associated with reduced expression of NK activatory receptors, cytotoxicity and 
cytokine production.157 I did not find that eomesodermin was down regulated in human NK cells 
exposed to AML blasts (data not shown). A further mechanism which may be interesting to explore, 
is high expression by AML blasts of the immunosuppressive type 1 immunoglobulin CD200 which 
has been linked to reduced NK cytotoxicity in AML.253  
Cytotoxicity and cytokine release from AML NK cells in response to PMA/ Ionomycin stimulation 
was preserved. This suggests that the immune editing process is targeting the immune synapse.  
Synapse dysfunction occurs in AML patient T cells where AML induces an inability in T cells to 
form functional immune synapses with AML blasts due to abnormal actin cytoskeletal formation.11 It 
is therefore possible that a similar mechanism may explain our data for NK cells. 
 
Do any cytotoxic abnormalities seen in AML normalise in remission? 
I showed that the reduced NK cytotoxicity towards leukaemia cells in AML partially normalises in 
remission. Degranulation function is restored, IFNγ production is partially restored, but TNFα 
production remains abnormal. A split in abnormal NK degranulation and cytokine-producing 
function is also seen after URD and cord blood SCT.254 In vitro experiments in mice show that NK 
cells exposed to AML blasts lose their cytokine-producing and cytotoxic function at different time 
points after exposure to disease.157 Different immunosuppressive drugs used post SCT affect NK 
receptor expression and cytotoxic function differentially: cyclosporin (CSA) is associated with 
NKG2A+ NCR + KIR- expressing NK cells and reduced IFNγ production but normal cytotoxic 
function, whereas Rapamycin and Mycophenolic acid (MPA) treatment (MPA is the active 
metabolite of Mycophenolate) is associated with NKG2A- NCR- KIR+ NK cells and the loss of both 
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cytotoxic and IFNγ production255. While there is less literature about the specific effects of induction 
chemotherapy on NK function it is possible that a similar mechanism could explain my results.  
In the process of NK maturation, NK cells acquire degranulation activity before they start producing 
IFNγ.111 As these effector functions are different to start with, it is not entirely surprising that 
exposure to AML cells might affect one more than the other. There is a wealth of evidence to suggest 
that production and secretion pathways of granules and cytokines are different: Cytokines are 
produced de novo on target cell stimulation, whereas granules are preformed. Perforin and cytokines 
are trafficked to the cell surface in separate carriers: vesicles and recycling endosomes respectively.71 
Vesicle secretion is highly polarised via the actin cytoskeleton for release only at the target cell 
synapse whereas cytokines are released at sites all over the cell surface.71 Also, signal transduction 
pathways may be different even downstream of the same receptor: Vav-1 is required for cytotoxicity 
but not IFNγ production,256 DAP12 is required for IFNγ secretion but not cytotoxicity,257 CD45 is 
required for cytokine production (via DAP12/syk/zap70) but not cytotoxicity (via DAP10),258 PI3K 
isoforms p110γ and p110δ are important in cytokine production but not cytotoxicity259 and 
Phospholipase C-2 is essential for cytotoxic granule secretion but not cytokine production.260 AML is 
heterogeneous and its effects on NK cells may also be heterogeneous. A larger study cohort enabling 
us to separate AML subtypes is required to understand immune editing in different AML groups. 
 
What is the repertoire of NK ligands on AML blasts?  
My results of NK ligand expression on AML blasts show no reduction in HLA class 1 in AML, low 
levels of MICA/B, and variable expression of death receptors 4 and 5, HLA E and Fas. Previous 
studies have indicated that HLA class 1 ligands are usually down-regulated in AML patients and that 
this is a major mechanism by which tumor cells escape NK mediated immune surveillance.163 We 
did not replicate this finding. Possibly this is because we used a pan class 1 antibody which included 
HLA-A, whereas it may be that only HLA B and C alleles class 1 alleles are down regulated in 
AML.163 My results showing low or negative MICA/B expression on the blast surface are supported 
by other studies showing similar results.164,261 It is also consistent with the mechanism that AML 
cells shed their surface MICA into the serum and thereby avoid the NKG2D-mediated immune 
response.164,166  
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Is expression of NK ligands on leukaemic blasts associated with changes in NK receptor 
phenotype or function? 
There appeared to be a pattern of individuals with high NKG2A having lower expression of the 
NKG2A ligand, HLA E but this correlation was not statistically significant and HLA E expression 
did not correlate with cytotoxic changes in AML. Upregulated HLA E has been reported in a number 
of tumours including lymphoma,262 colon cancer,263 melanoma264 and AML.265 HLA E expression on 
AML blasts is induced by IFNγ produced by CD56 bright NK cells post SCT. As higher HLA E 
expression encourages NKG2A-mediated inhibition of NK cells, modification of HLA E is therefore 
an example of tumour immune evasion.265 Tumor expression of HLA E may be reduced with 
selenium treatment leading to increased killing of AML tumour cells via less NKG2A-mediated 
inhibition266 indicating that HLA E expression may be exploitable in a clinical setting. We did not 
find a relationship between expression of HLA E on blasts and NK cytotoxicity or response to 
treatment in our cohort, however. The exact role HLA E in AML has yet to be clarified. This may be 
due to the small cohort size, or it could indicate that no relationship between HLA E and AML 
exists. Certainly data about its role in other cancers has been conflicting with high HLA E expression 
associated with both better prognosis267 and worse prognosis in colon cancer.268 One further 
possibility is that the role of HLA E in AML has a greater effect on the NKG2A expressed by 
cytotoxic T cells and further work should be directed towards T cells rather than NK cells.269 
 
Do individuals with abnormal phenotype have worse cytotoxic function? 
Different abnormalities in NK surface receptor phenotype are associated with different abnormalities 
in function: high NKG2A being associated with reduced TNFα production and low NKp46 
expression being associated with reduced degranulation and IFNγ production. This separation of 
different functions is similar to that occurring in remission discussed above under aim 4 and may be 
explained in a similar manner. My findings that raised NKG2A in AML patients is associated with 
reduced cytotoxicity are consistent with data from stem cell transplantation (SCT), showing that 
raised NKG2A levels are associated with reduced cytotoxicity and a reduced GVL effect towards 
AML.270 This paper also suggests that NKG2A-mediated NK interactions may be more important in 
inhibiting GVL towards AML post SCT than the absence of a KIR-KIR ligand mismatch, which also 
corroborates my data finding no clear effect of a mismatch on cytotoxic NK function. 
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Is it possible to induce abnormalities by exposing normal NK cells to AML blasts?  
Since abnormal NK cells were found in AML patients, and remission reversed some of the abnormal 
phenotypic and functional changes in AML-NK cells, I explored the ability of primary AML blasts 
to modify NKp46 and NKG2A expression and effector function in healthy control NK cells. 
Although there was no change in NKp46 and NKG2A expression, co-culture of AML blasts with 
healthy donor NK cells impaired their effector function and cytotoxicity. These findings imply that 
while NK cells from healthy donors can exert anti-leukaemia effects, the immunotherapeutic benefit 
from NK cell immunotherapy and the GVL effect may be limited by an immune-editing function of 
AML cells. Il-2 is often given as part of adoptive therapy to support NK expansion when NK are 
infused into AML patients. I therefore investigated whether this cytokine might prevent immune 
editing by AML. In my experiments, a similar pattern of NK inhibition was seen with and without 
IL-2, indicating that Il-2 does not overcome the immune editing effects of AML. Future studies to 
investigate whether the addition of cytokines such as Il-15, IFNγ or TGF-1 inhibitors 250 could 
circumvent this immune editing process and improve the function of NK immunotherapy will be 
interesting to pursue. 
 
 
 
The main limitation of this work is that my study has limited power. More experiments on greater 
numbers of patients may strengthen my findings. As AML is a relatively rare disease, I was curtailed 
in collecting samples from individuals as and when they presented between September 2009 and 
early 2012. However, my data demonstrate significant abnormalities in the NK response to AML 
supporting the concept that immune editing by AML facilitates its survival. 
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Chapter 6 Using NK studies to predict clinical outcome in AML 
In the previous chapter, I demonstrated abnormalities in the NK-mediated immune response towards 
AML and showed results relevant to the concept of immune editing in this disease.  My data also 
provide functional support for the importance of the NK-mediated immune response to AML. What 
has not yet been shown is whether studying NK cell responses can help predict the outcome of 
patients with AML. I have collected blood samples, cytogenetic and clinical data from AML patients 
between 2009 and 2012 and have recorded the treatment regimen and outcomes of these patients. In 
this chapter I test whether abnormalities in NK cell phenotype and function predict clinical outcome 
in AML.  
6.1 Background 
As discussed in section 1.1, there are a number of known factors which impact upon clinical outcome 
in AML. These can be divided into factors associated with the patient and factors associated with the 
disease. Patient factors associated with poor clinical outcome include advanced age and performance 
status (how able the patient is to carry out the activities of daily living).271 Disease related factors 
include whether AML has occured secondary to therapy for a previous malignancy or other 
haematological disorder, 272 as well as cytogenetic abnormalities2,3 273 and molecular mutations.274 It 
is important to note that cytogenetic and molecular changes can help predict good as well as poor 
outcome (see table 1.1). Another patient related factor is the strength of NK-mediated immunity 
towards AML. This has not yet been looked at and I will do so in this chapter, which addresses the 
following aims: 
6.2 Aims of this chapter 
i-What are the clinical outcomes of the Hammersmith Hospital cohort of AML patients? 
ii-Does having secondary AML impact upon NK immunity and outcome compared with de novo 
AML? 
iii-Do NK surface receptor abnormalities in AML affect response to treatment? 
iv- Do cytotoxic and effector cytokine abnormalities in AML predict response to treatment? 
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6.3 Results 
6.3-i-Clinical Outcomes 
Clinical outcomes of the 32 AML patients studied in chapter 5 are presented in table 6. 1. This cohort 
had a high proportion of poor-risk patients: half had secondary AML (see table 5.1 in previous 
chapter) and nearly half went on to have stem cell transplantation (SCT) in first remission. This 
makes looking at typical outcome measures such as relapse and survival more difficult because any 
data collected post SCT will correspond to donor NK immunity rather than patient. However, 
response to the first course of chemotherapy is a valuable outcome measure, which I have for all but 
one patient (who left the UK before treatment). In this cohort, only half the patients achieved 
complete remission after the first course of chemotherapy (DA: Daunorubicin and Cytarabine), with 
a further five patients doing so after a second or occasionally a third course of salvage treatment 
(typically Flag-Ida chemotherapy: Fludarabine, Cytarabine, GCSF and Idarubicin). A third of 
patients either did not respond at all or were too frail to undergo chemotherapy treatment.  
Table 6.1 Clinical outcomes of AML patients 
Clinical Outcomes No. (%) 
No. patients 31 (1 outcome unknown: refused Rx, left UK) 
Complete remission after #1 (DA 3+10) 15 (48%) 
Eventual CR (after 2-3#s Flag Ida) 5   (16%) 
No Response to chemo/not fit for Rx  11 (36%) 
Outcome at 6 months post chemotherapy for those achieving first remission: n=19 
SCT in CR1 8 (two relapsed < 1 yr, both died, 6 alive in CR) 
SCT in CR2  1 (currently in CR 6 months post SCT) 
Relapsed, no further Rx 3  
Alive without SCT 2  
Non-leukaemia death 2 (one sepsis during #2, one cardiac during #3) 
Not yet 6 months post chemo but in CR 4  
Abbreviations: CR, complete remission; SCT stem cell transplantation; Rx, treatment 
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6.3-ii-Does having secondary AML impact upon NK immunity and outcome compared with de 
novo AML? 
In view of the large numbers of secondary AML patients in this cohort, and my results from chapter 
4 suggesting that secondary AML may have distinct kinetics which facilitiate NK-mediated 
immunity in AML, I investigated whether this predicted response to chemotherapy. Secondary AML 
is generally thought to be associated with poor outcome.272 In this cohort, as figure 6.1a shows, there 
was no difference in response to induction chemotherapy between patients with secondary and de 
novo AML. Surprisingly, patients with secondary AML were as likely to respond as de novo AML. 
This corresponds to my functional data (fig. 6.1b) showing similar NK cytotoxicity in secondary and 
de novo AML. 
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Figure 6.1 Secondary versus de novo AML: response to treatment and NK cytotoxicity. There is no 
significant difference between those with de novo AML (n=16) and secondary AML (n=16) with respect 
to a) response to first line treatment (Chi square test) and b) NK cytotoxicity (unpaired t tests). Grey 
bars represent proportion of patients achieving complete remission.  
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6.3-iii-Do NK surface receptor abnormalities affect response to treatment? 
Those with an abnormally high frequency of NKG2A expressing NK cells, were less likely to 
respond to chemotherapy (31% achieved CR compared to 78% of those with a frequency lower than 
the median, p=0.041). Interestingly, individuals with low NKp46 expression at presentation did not 
have a higher risk of failing chemotherapy (fig 6.2). 
 
Figure 6.2 NK surface receptor phenotype and response to AML chemotherapy. Receptor expression in 
32 AML patients was assessed. Patients were divided into those whose levels of NKG2A and NKp46 
were above or below the median. Figure shows that high NKG2A predicted poor response to treatment. 
Low NKp46 did not. 
 
Having shown that frequency of NKG2A expressing NK cells predicted response to treatment, I 
looked whether the combination of levels of NKG2A and expression of its ligand HLA E on AML 
blasts at diagnosis could be an even more useful marker for predicting response. Using my data in 
chapter 5 (fig. 5.12 showing that patients with high NKG2A often have low blast HLA E 
expression), I created a ratio of HLA E to NKG2A expression. Figure 6.3 shows that this ratio is a 
helpful predictor of treatment outcome with higher ratios indicating better response. 
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Figure 6.3 NKG2A and HLA E together helped predict response to treatment. a) Non-responders (in 
red) showed a pattern of higher NK NKG2A levels and lower blast HLA E expression than responders 
(in black) b) The HLA E/NKG2A ratio is significantly higher in those who respond to AML treatment. 
6.3-iv-Do cytotoxic and effector cytokine abnormalities in AML predict response to treatment? 
Looking at abnormalities at AML presentation using median cut-offs to separate those with high and 
low cytotoxicity and effector cytokine producing function, NK production of TNFα at D0 predicted 
those who will achieve remission with induction chemotherapy. All AML patients presenting with 
levels of TNFα production greater than the median achieved CR, compared to only 39% (9/23) of 
patients with TNFα production below the median (p=0.041) (fig. 6.4a). There was no impact of NK 
degranulation or IFNγ production at diagnosis on the probability of achieving remission post-
chemotherapy. Also, those who did not respond to induction chemotherapy had TNFα levels 
significantly lower than normal controls (p=0.019) (fig. 6.4b), with a possible (but not statistically 
significant) gradient where higher D0 TNFα indicated more rapid response. These results suggest 
that TNFα could possibly be used as a marker to predict chemotherapy response. 
 
 
NC
 N
KG
2A
AM
L N
KG
2A
HL
A 
E
0
20
40
60
80
100
%
 N
K
 e
xp
re
ss
io
n
%
 N
K
 e
xp
re
ss
io
n
No
n r
es
po
nd
ers
Re
sp
on
de
rs
0
2
4
6
8 0.0315p= *
H
LA
 E
/N
K
G
2A
 r
at
io
a b
116 
 
          
            
No
rm
al 
Co
ntr
ols
CR
 po
st 
#1
CR
 po
st 
# 2
-3
No
n r
es
po
nd
ers
0.1
1
10
100
0.0191p=
0.1549p=
p=
p=
0.5448
0.9227
0.3352p=
%
 T
NF
α
      
Figure 6.4 NK cytotoxicity and response to treatment a) TNFα production at D0 predicted for achieving 
remission after initial chemotherapy (Chi2 test) b) TNFα production from CD56+ CD3- cells against 
K562 leukaemic targets at AML presentation: Non-responders produced significantly less than normal 
controls and there appears to be a possible a dose effect with greater production of TNFα at 
presentation corresponding to earlier treatment response   
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6.4 Discussion 
Clinical outcomes: Clinical outcome data in this cohort of patients are limited by several factors. 
First, as this study was conceived of, performed and analyzed within the time frame of a PhD, follow 
up has been relatively short. This matters less for the patients recruited at the start of the study, who 
have been followed up for two years, the time interval during which AML relapse risk is highest.275 
However, for patients recruited towards the end of the study (and 13% were within 6 months of 
diagnosis at the time of analysis), the risk of relapse is still high. These later patients would therefore 
need to be excluded from any outcome measures beyond response to induction. Another subset of 
patients for whom outcome measures are limited, are those who underwent SCT. This group 
accounts for a substantial proportion of my patients: nearly a third underwent SCT within 6 months 
of initial treatment. This reflects the relatively high proportion of individuals not responding to initial 
induction, as well as a high proportion of secondary AML many of whom were put forward for early 
SCT by virtue of this regardless of early response. While most patients who underwent SCT have so 
far done well, with 78% still in remission at time of analysis, this remission does not reflect their 
own immune surveillance of AML, but rather that of a normal donor and therefore is not of use for 
the purposes of this study. These factors mean that many of the usual outcome measures in AML 
patients receiving chemotherapy, that is, relapse-free survival at 3 years, relapse-free survival at 5 
years and overall survival, are not applicable to this cohort. Working within these limitations, I 
measure of outcome in this study as response to induction therapy. 
Secondary AML and outcome: Patients with secondary AML were not different to the patients with 
de novo AML, either in response to treatment, or in terms of NK-mediated cytotoxicity and effector 
cytokine production. This contrasts with other studies where secondary AML is generally associated 
with poor outcome.272 Although recruited sequentially, the secondary AML patients in this cohort 
had a genetic and molecular profile of slightly better risk than is typical in secondary AML: While 
50% (8/16) had complex karyotype, monosomies, abnormal 3 or 7, or the MLL mutation, 31% (5/16) 
had a normal karyotype. 
A further possibility is that abnormalities in NK phenotype and function are independent of other 
risk factors such as having secondary AML. This could be interpreted as a strength, supporting the 
concept that NK function is important for outcome in all individuals with AML and that the process 
of immune editing occurs irrespective of the trigger for disease. 
NK surface receptor abnormalities and outcome: I show that levels of NKG2A expressing NK cells 
in AML patients can help predict response to chemotherapy treatment: only 30% of those whose NK 
cells express abnormally high NKG2A levels achieved complete remission after the first cycle of 
chemotherapy. This compares to 80% of those whose NKG2A levels are lower than the median 
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(p=0.041). This clinical evidence supports my data from chapter 5 and further indicates that NKG2A 
levels are important in AML. 
While up regulation of NKG2A is an example of AML-induced immune editing of NK cells to 
facilitate blast survival, modification of HLA E expression is something that the blast can itself 
adjust in an attempt to evade immune control. As NKG2A and HLA E levels appear to be linked in 
AML patients, combining the two factors may provide a superior method of predicting response than 
either one alone. I found that HLA E expression alone does not predict for treatment outcome (data 
not shown) as there are some patients who do not down regulate their HLA E and still have a poor 
response to treatment. However, when we combine HLA E levels as a ratio to NKG2A, we see a 
clear association between low ratio and poor response (p=0.0315), indicating that this may be a 
helpful predictor of how the process of immune editing/escape may influence a patient’s outcome to 
chemotherapy. It will be important to validate this finding in prospective studies.  
Cytotoxic abnormalities and outcome: I show that individuals not responding to first line 
chemotherapy are more likely to produce low levels of TNFα at diagnosis than patients who achieve 
remission. TNFα could therefore potentially be used as a marker to predict those patients to whom 
either a palliative approach or a more aggressive induction may be more suitable, thus avoiding 
unnecessary or unhelpful treatment.  
My findings are consistent with work showing that reduced NK-mediated cytotoxicity is associated 
with poor outcome post AML treatment13 and is consistent with the concept of immune editing of 
NK cells by AML. Why this process targets NKG2A and TNFα particularly is as yet unknown. 
Certainly, as mentioned in the discussion for chapter 5, there are a myriad of reasons why immune 
editing might target one cytotoxic mechanism and not another owing to the very different cellular 
pathways involved.  
The interpretation of these findings needs to be cautious. The selection of the sample (see discussion 
above) and the short follow up limit the inferences that can be drawn. Further studies should attempt 
to replicate this finding and evaluate the potential role of TNFα and NKG2A as predictors of clinical 
outcome. 
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Chapter 7 Discussion 
This thesis has investigated the role of NK cell immunity in AML. Because this is a very extensive 
topic, three main questions have been considered, questions which seemed central to identifying a 
potential role for NK cells in the immune control of AML: 
1. Do individual killer immunoglobulin receptor (KIR) genes (coding for specific NK surface 
receptors) affect the risk of developing leukaemia and the outcome of treatment aimed at cure, i.e. 
chemotherapy and stem cell transplantation? 
2. Are NK cells abnormal in surface phenotype or cytotoxic function in AML patients and does the 
individual’s NK cell receptor profile or cytotoxicity affect outcome of leukaemia remission induction 
treatment? 
3. Are abnormalities found in NK cells induced by the AML or do they occur because of genetic 
predisposition?  
These questions have been addressed in the previous chapters. Below I summarise the findings. 
 
7.1 Summarised findings addressing aims of PhD 
7.1-i-Do individual killer immunoglobulin receptor (KIR) genes (coding for specific NK surface 
receptors) affect the risk of developing leukaemia and the outcome of treatment aimed at cure, 
ie. chemotherapy and stem cell transplantation? 
 
Finding: KIR2DS2 and greater numbers of activatory KIRs may be protective against the 
development of secondary AML and the activatory KIR haplotype B may specifically protect 
against therapy-related AML  
Chapter four assessed the role of KIRs in AML patients receiving chemotherapy. This large cohort of 
499 AML patients enabled me to investigate firstly whether KIR genotype was different in 
individuals developing leukaemia compared to normal individuals and, secondly, whether KIR 
genotype predicted outcome. I found that individuals with secondary AML had lower rates of the 
activatory KIR2DS2, as well as lower total numbers of activatory KIRs compared to the normal 
donor population and those with de novo AML, suggesting that activatory KIRs and in particular 
KIR2DS2 may be protective against development of secondary AML. The subset of secondary AML 
who developed their disease following therapy for a previous malignancy (t-AML) were also 
significantly less likely to possess the activatory KIR haplotype B suggesting that this KIR haplotype 
may protect individuals from developing t-AML. 
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Finding: The largely activatory B haplotype KIR genes 2DS1, 3DS1, 2DL5a were associated 
with reduced relapse after SCT for AML but not for other haematological malignancies 
Chapter 3 assessed the role of KIRs in stem cell transplantation. Results are presented showing that 
AML patients receiving matched sibling T deplete transplants from donors with 3 specific 
‘favourable’ KIRs (encoding mostly activatory receptors), were four times less likely to relapse than 
patients whose donors did not possess these genes (p=0.02). As the study cohort included those with 
lymphoid malignancies as well as chronic myeloid leukaemias, it was possible to assess whether the 
effect of KIRs was disease specific. It was found that donor ‘favourable’ KIRs only conferred benefit 
to patients with acute myeloid leukaemia indicating a protective process specific to this disease.  
Finding: Neither KIR genotype, nor KIR ligands predicted outcome in AML patients receiving 
chemotherapy 
Following the finding presented in chapter 3 that donor KIRs predicted relapse risk in AML patients 
receiving SCT as well as several studies showing the importance of missing KIR ligands in 
predicting outcome of SCT, the next step was to explore KIR groups in AML patients receiving 
standard initial remission induction chemotherapy (chapter 4).  The lack of any impact of KIR 
genotype or missing KIR ligands on outcome after chemotherapy suggests that KIR group genotype 
and expression only impact the outcome of treatment in the context of allogeneic stem cell 
transplantation. This could either be because alloreacting NK cells also use non-KIR related genetic 
differences to exert an antileukemic effect, or because the immunoablation of SCT provides a unique 
milieu where newly generated donor NK cells can exert a GVL effect.  
Relevance of KIR results: KIRs are an important group of NK surface receptors which when bound 
to their ligands, mediate NK education, self-tolerance and recognition of target cells via inhibition or 
activation of NK cell activity. The fact that within the human population there is distinct variability 
in the inheritance of KIR genes leading to a range of genotypes, led me to investigate whether this 
variability might account for some of the variability in predisposition for, and outcome from 
leukaemia. It appears that this is indeed the case in AML.  
Implications of KIR results for biological understanding/basic research: As KIR are largely confined 
to NK cells (and a very small subset of T cells), the first conclusion which can be drawn from these 
results, is that NK cells do play an important role in the immune response to AML. However, the fact 
that KIR2DS2 only conferred benefit against the development of secondary AML indicates that NK 
cells only affect the course of disease when leukaemia develops over a longer time scale – more 
likely to occur in tAML in contrast to de novo AML where rapid accumulation of leukaemic blasts 
overwhelms the NK response. This has implications for understanding the kinetics of the NK 
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response to AML.  That KIR genotype can influence patient outcome, supports investment in further 
functional studies to delineate NK-mediated immune responses to leukaemia. Both in AML patients 
treated with SCT and those receiving chemotherapy, the KIRs which conferred most benefit encoded 
activatory receptors.  This suggests that individuals with an NK cell KIR gene profile balanced in 
favour of NK activation are better equipped to kill AML tumour cells. Further identification of the 
ligands for activatory receptors and the expression (or modification of expression) of these ligands 
on the AML target in the evasion of NK mediated immune response would therefore be worthwhile.  
Implications of KIR results for risk stratification: Many factors improve the likelihood of a 
successful outcome after SCT as discussed in previous chapters. Most donor-related factors 
identified relate to the T cell response. These include modifying the degree of HLA match to 
influence the GVHD/GVL balance and using donor sex mismatch to provide female donor T cells 
specific for recipient male minor histocompatiblity antigens encoded by Y-chromosome genes. My 
results support the increasing evidence that the NK cell-mediated immune response is important in 
the SCT setting and that selecting donors with an activatory KIR genotype may improve patient 
outcome.  
The findings presented in this thesis that KIR2DS2 may be protective against secondary AML could 
enhance risk stratification of patients with myelodysplastic syndrome. Currently the IPSS score takes 
into account factors known to impact risk of development of AML. It would be of interest to explore 
whether KIR genotype might be an additional risk factor for disease progression. It will also be of 
interest to validate whether individuals with poor risk KIR genotypes (low numbers of activatory 
KIRs/negative for KIR2DS2/negative for B haplotype), are more likely to develop AML secondary 
to treatment for haematological diseases such as Hodgkin’s and non Hodgkin’s lymphomas, 
Myeloma and Waldenstrom’s. If so, those deemed higher risk could be counselled appropriately, 
screened more regularly, and perhaps have it built it into their initial treatment algorithm to be 
particularly careful with alkylating agents and other particularly leukaemogenic drugs.  
Implications of KIR results for future therapeutic interventions: The fact that KIR2DS2 only 
conferred benefit against the development of secondary and not de novo AML suggests that optimal 
NK responses do not occur in the presence of very rapid accumulation of leukaemic blasts. This 
supports the practice of reducing the blast count as much as possible before attempting NK-based 
immunological therapies. Strategies to improve the NK-mediated immune response to AML could 
incorporate KIR genotype. For example, adoptive transfer of NK cells expressing high numbers of 
activatory KIRs either by choosing donors according to genotype, or by developing ways to 
manipulate grafts to increase KIR expression. 
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7.1-ii- Are NK cells abnormal in surface phenotype or cytotoxic function in AML patients and 
does the individual’s NK cell receptor profile or cytotoxicity affect outcome of leukaemia 
remission induction treatment? 
 
Finding: AML patients exhibited abnormal NK surface receptor phenotype with higher 
numbers of NK cells expressing inhibitory NKG2A receptors and lower NK cell expression of 
activatory NKp46 receptors 
Chapter 5 assessed the surface phenotype and cytotoxicity of NK cells in AML patients at 
presentation and remission compared with normal controls. The results demonstrate a distinct change 
in the balance of NK activatory and inhibitory receptor expression in AML patients biased towards 
inhibition of NK cell immunity.  
Finding: AML patients exhibit reduced NK cytotoxicity both in terms of the ability to 
degranulate and to produce cytotoxic cytokines IFNγ and TNFα 
This striking finding of a marked reduction in the ability of NK cells to kill leukaemic target cells in 
AML patients supports the hypotheses that the NK response is important in AML, and that 
successful immune editing of NK cells by AML cells occurs, favouring evasion of NK control and 
survival of AML blasts. Interestingly, this effect was not specific to KIR expressing cells but was 
found in all NK cells. 
Finding: Surface receptor abnormalities and cytotoxic abnormalities only partially normalise 
in complete remission 
While abnormal NKp46 expression, degranulation and IFNγ production all normalised when AML 
patients achieved remission, both NKG2A expression and TNFα production remained abnormal. 
This may be a mechanism contributing to the high relapse rates in AML indicating that the immune 
editing of NK cells persists, either because only small levels of residual leukaemia are needed to 
maintain the defective phenotype or because the effect involves haematopoietic stem cells which 
continue to produce abnormal NK cells. NKG2A expression and TNFα production were also the 
factors that best predicted response to treatment, and future studies focusing on these molecules are 
indicated.  
Finding: Expression of NKG2A together with its ligand HLA E on AML blasts at presentation, 
and TNFα production predicts response to remission induction treatment in AML 
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Patients failing to achieve remission had higher NKG2A levels and lower HLA E to NKG2A ratios 
than non-responders. Lower TNFα production at presentation was also a risk factor for treatment 
failure. 
Implications of functional results for biological understanding/basic research: The work presented 
in this thesis adds potentially useful data to emerging evidence that NK immune responses in AML 
are defective and that patients with more functional NK cells do better. However, links between 
these findings and clinical outcomes still remain largely circumstantial. Therefore, my findings serve 
best as hypothesis-generating starting points to better define NK cell / AML interactions.    
Implications of functional results for risk stratification: My results indicate that NKG2A on NK cells 
and HLA-E on AML blasts as well as the ability of NK cells to produce TNFα, could be incorporated 
into a prognostic model for predicting remission induction. This could aid current algorithms used to 
stratify AML patients into those suitable for standard chemotherapy, and those for whom a more 
intensive regimen, or a palliative approach would be more appropriate. 
Implications of functional results for future therapeutic interventions: These findings suggest that 
treatment outcome in AML could be improved by the adoptive transfer of NK cells from healthy 
donors in remission at a time when the leukaemia burden is low enough to avoid immune editing of 
infused NK cells. Alternatively it would be worthwhile exploring whether cytokines such as IL-15 
could normalise the NK cell population and improve immune control of residual leukaemia in 
remission.250 Encouraging tumour cell expression of NK receptor ligands such as HLA E266 is also a 
possibility in AML. The induction of higher TNFα production by NK cells may help patients 
respond to chemotherapy and would also be a worthwhile research avenue to pursue. 
7.1-iii- Are abnormalities found in NK cells induced by the AML or do they occur because of 
genetic predisposition?  
Finding: Abnormal phenotype and function can be induced in normal NK cells by exposure to 
AML blasts  
This indicates that the abnormalities in surface phenotype and cytotoxic function I found in the NK-
mediated immune response in AML patients occur through immune editing and not because of an 
innate defect in the patients’ NK cells.  This provides experimental support for a dynamic interaction 
between AML and NK cells. That AML cells “need” to regulate NK function strongly suggests that 
healthy unmodified NK cells could have the potential to control leukaemia and supports attempts to 
improve outcome for AML by NK cell therapy. However the rapid and efficient disarming of normal 
NK cells by AML blasts raises the problem of how to deliver NK cell therapy without the cells being 
rendered ineffective.  
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7.2 Limitations of this thesis 
 
7.2-i- Biological constraints:  
Incomplete correspondence between genotype and phenotype: There will be individuals who possess 
the KIR gene of interest but do not express the receptor on the surface of their NK cells. As 
discussed in chapter 4, this problem is less pernicious in the study of KIR genes than for many other 
genes as there is relatively good correlation (about 94%) between genotype and phenotype.222 This is 
however, something that needs to be taken into consideration.  
KIRs are also expressed on a small fraction of T cells: Focus on NK function may have been too 
narrow. Mechanistic explanations for functional differences in KIR groups that explain the anti-
leukaemic potential are lacking. More extended functional studies looking at factors such as 
licensing of NK by AML, SCID mouse AML models, exploring differential disease control by NK 
according to leukaemia subtypes as well as the role of cytokine production will all help to expand 
our understanding of this area. 
 
7.2-ii- Clinical constraints:  
Limited follow up: Longer follow-up of the Hammersmith Hospital series to enable analysis of 
relapse and overall survival would have been useful. This would allow me to assess other factors 
such as the role of KIRs and leukaemia-induced NK functional abnormalities in relapse outcome, 
exploring age effects and time to remission, all of which would enrich this study.  
Limited scope for analysing different types of AML: A larger cohort of patients for my functional 
study with longer follow up would have facilitated investigation of different subgroups of AML. For 
example, it would have been interesting to explore AML M3 – maybe this specific AML subtype 
with its favourable outcome is affected differently. As my functional cohort is weighted towards 
poor risk patients, a larger cohort of good and intermediate risk patients may show bigger effects of 
immune surveillance which are masked by the preponderance of poor risk patients who may do 
poorly whatever treatment we give and whatever NK-related genetic and functional equipment they 
possess. My results from chapter 4 indicate that further investigation of MDS/AML and therapy 
related-AML is also warranted. 
7.2-iii Statistical constraints: 
Limited power: As with many scientific studies, greater power could improve the accuracy of my 
results and reduce the risk of committing Type 1 errors. Larger cohorts for my studies would also 
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have enabled me to investigate different AML subsets and better take into account known risk 
factors such as cytogenetics, which could strengthen my findings.  
Selection bias: All three studies assume the sample investigated represents the general AML 
population. This is of particular concern with the third prospective study detailed in chapters 5 and 6 
where I extrapolate conclusions to the whole AML patient population from findings generated from a 
study of only 32 patients. To minimise selection bias, I included consecutive new AML patients 
missing only those who arrived and started chemotherapy on a weekend. All patients I approached 
consented to the study.  In the SCT study the fact that matched sibling SCT was the only mode of 
treatment meant that the AML population I investigated was higher than average risk and that 
conclusions from this study cannot therefore be extrapolated to other transplant situations.  
The MRC cohort, as discussed in chapter 4, draws from the MRC AML 10 and 15 trials. While the 
original trials were designed to minimise selection bias as far as possible, the present study cohort 
was necessarily constrained by the DNA samples available. There was therefore, a higher proportion 
of patients from more recent time points (where samples had not been used up in previous studies). 
However, within the population for whom samples were available, we attempted to ensure that the 
cohort was representative of the general AML population in terms of age, morphological subtypes 
and cytogenetic risk groups to minimise this problem.  
Multiple testing:  In all three studies, multiple testing is a potential source of random error (the 
increased probability of statistical Type I error; that is, mistaking a random finding for a statistically 
significant one). I tried to minimise this by making my research as hypothesis-driven as possible, 
attempting to answer only specific pre-determined questions. The MRC observational and AML 
prospective study were however, by nature exploratory, and therefore some non-hypothesis-based 
findings with significant differences emerged during the analysis, which we retrospectively sought to 
validate. To reduce error due to multiple testing I decreased the p value indicative of significance in 
the MRC study to <0.01. 
Limited outcome measures due to early death or SCT: In spite of attempts to minimise selection bias, 
the prospectively collected AML cohort included a preponderance of patients with poor risk and/or 
secondary AML which meant that a greater proportion of patients either did not respond to 
chemotherapy, or had an early SCT to prevent relapse. While this strategy of early SCT worked, in 
that the majority of those undergoing SCT in first remission were still in remission at the time of 
writing, it limited my analysis as I could not use the typical measures of disease relapse or overall 
survival to assess outcome in this cohort.  
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7.3 Future directions 
7.3-i- Clinical/therapeutic future directions 
a) Studying KIR genotype in patients with myelodysplastic syndrome (MDS) and in patients after 
therapy for other haematological malignancies: My finding that 2DS2 appears to protect against 
secondary AML encourages me to study MDS patients to see whether KIR2DS2 is under-
represented in those who go on to develop AML. Similarly, it will be important to study a cohort of 
patients after treatment for haematological malignancies such as Hodgkin’s, NHL and myeloma 
(who have a significant increased risk of secondary AML) to see whether poor risk KIR genes 
segregate to these individuals. Such data would have important implications in helping to predict 
secondary AML patients and could augment current predictive algorithms.  In particular it could help 
select individuals for earlier therapeutic interventions and SCT and identify patients in whom a 
watch and wait strategy and/or less intensive treatment could be adopted. This study would be 
relatively straightforward to carry out in a unit with a large cohort of MDS and lymphoma patients. 
The time lag for development of AML from MDS would be suited to a retrospective observational 
study. 
b) Blocking immune editing with new therapeutic agents: After SCT, high IL-15 levels have been 
demonstrated to be associated with higher numbers of activatory receptors249 and this cytokine has 
been used in vitro to induce expression of activatory receptors in cells from AML patients.250 This 
work suggests that it may be possible to use IL-15 to reverse some of the changes we found in NK 
cells. Selenium can reduce expression of HLA-E and might thereby enhance AML killing by NK 
cells.266  A trial using selenium to block HLA-E and improve the HLA E/NKG2A ratio in AML 
patients should be considered.  
c) Clinical trials using donors with activatory/2DS2/Favourable KIRs for SCT and as donors for 
adoptive NK immunotherapy: My results in chapters 3 and 4 suggest that KIR genotype may 
improve NK mediated immune surveillance. Incorporating this into donor selection procedures for 
SCT and adoptive NK immunotherapy could improve outcome for patients receiving SCT from HLA 
matched donors and a prospective study using selected donors would be worthwhile.  The concept of 
“favourable KIR” donors could also be extended beyond the SCT setting to treatment of AML in 
remission with alloreactive NK cells from selected donors. Especially where the patients’ KIR 
groups are unfavourable, the use of allogeneic NK cells could have greater antileukemic potential 
than autologous NK cells.  
d) Investigating Bortezomib to up-regulate TRAIL ligands: Bortezomib can be used to up-regulate 
the DR4/5 ligands for TRAIL. This has been shown in chronic myeloid leukaemia to enhance 
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susceptibility of quiescent CD34+ CML cells to cytotoxicity by in vitro expanded natural killer 
cells.276 Further investigation of the role of the TRAIL-mediated death receptor pathway of NK 
cytotoxicity and the potential to enhance NK cytotoxicity to AML stem cells would therefore be 
important to explore. 
e) Using antibodies to block negative KIRs: Preliminary studies have shown that antibodies can be 
used clinically to block inhibitory KIRs in AML patients.277 In view of my results highlighting the 
role of activatory KIRs, further exploration of this antibody to alter the balance between activatory 
and inhibitory KIRs in AML patients using these agents will be interesting. 
 
7.3-ii- Biological aspects - future directions 
a) Further functional work to elucidate mechanisms of AML-initiated immune editing of NK cells:  
1) Co-culture studies should be repeated with a larger group of normal individuals using different 
AML subtypes to delineate whether certain healthy individuals are more susceptible to immune 
editing than others and whether certain AML subtypes are more immune-modulatory than others. I 
would also want to explore whether the suppression is mediated by all AML blasts or CD38 negative 
CD34 positive AML stem cell like cells.    
2) Although my data so far suggest that cell contact between blasts and NK cells is necessary for 
immune editing to occur, it should be confirmed using trans-well experiments and supernatants to 
assess the role of secreted factors more carefully.    
3) Further studies using confocal microscopy and assessment of the cytoskeleton could be used to 
explore the immune synapse between NK cells and AML to determine whether there are similar 
abnormalities to the findings in T cells.11  
4) Investigations of molecular mechanisms underlying immune editing by AML: in my initial 
studies, I could not identify any candidate enzymes or transcription factors (IDO or eomesodermin), 
to explain abnormalities seen in NK cells in AML patients. The role of CD200 expression on blasts 
would be of relevance here.253  
b) Identifying the ligands for activatory KIRs on blasts: The results in this thesis support the growing 
body of evidence that NK cells expressing activatory KIRs are particularly important in mediating 
the NK response towards AML. However, identification of the exact ligands for many activatory 
KIRs (as well as other NK receptors such as the NCRs) remains elusive. Candidates include heat 
shock proteins and as yet unknown leukaemia antigens. Work to identify these ligands could inform 
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functional studies. For example, ligand expression on blasts could be manipulated to minimise 
immune evasion with therapeutic implications. 
7.4.  Immunotherapy for AML – concluding remarks  
While the results in this thesis provide strong evidence for the importance of NK cells in the immune 
response against AML, there is evidence for similar immune editing of T cells in AML raising the 
questions: how much do the innate and adaptive immune responses to AML interact? And do T cells 
or NK cells dominate in AML immune regulation? A further complexity that remains to be 
addressed is the role of the bone marrow milieu and in particular the role of mesenchymal stromal 
cells (MSC) in modulating immune responses to AML. In a larger context, despite accumulating 
evidence for the interaction of the immune system with AML, it is as yet unclear how powerful the 
immune system is in shaping the outcome of AML in comparison with better-defined prognostic 
indicators. These questions seem important because they underpin the level of enthusiasm we should 
have for developing immunotherapy strategies to augment NK or T cell (or possibly B cell) 
responses in AML to achieve sustained remissions.  
Clear evidence for T cell responses against AML comes from the SCT setting, where AML-specific 
T cells in the graft as well as donor lymphocyte infusions correlate with improved GVL. Further 
evidence comes from work with tumour vaccinations against leukaemia antigens such as Wilms 
tumor protein 1 (WT1) and PR1 (derived from proteinase 3) showing anti-leukaemic responses from 
antigen specific T cells which correlate with clinical response.22 There has been less work focusing 
on the B cell response to AML. Humoral responses have however, been very useful in the context of 
serum screening of tissue banks and cell lines which can direct us to new leukaemia associated 
antigens278,279. The immune cells in the bone marrow provide a special milieu for AML. MSC inhibit 
normal tumour apoptosis and provide a tolerant environment for AML to grow280,281. Induced 
abnormalilites in the MSC microenvironment can induce leukaemia282 and blocking chemokines 
such as CXCR4 can impair the bone marrow’s role as a tumor sanctuary from chemotherapy283 . The 
NK response is therefore by no means the only component of the immune reaction against AML.  It 
may be that some subsets of AML are more T-cell than NK-cell controlled. Mutations in the NPM1 
gene are a relatively common finding in AML284. Recent work confirms that in the majority of AML 
patients with this mutation, NPM1 induces specific CD4 and CD8 T cell responses which may 
explain why mutated NPM1 is associated with a good prognosis285. A patient who maintained a long-
term response after a rare spontaneous remission to AML 11 years before, shows that while T cell 
responses are no different to normal, NK tumour responses remain increased suggesting that NKs 
may have a particular role in maintenance of long term remission.286 
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In considering the role of immunity in AML we have to be mindful that the immune milieu may be 
drastically different at presentation, at remission and again at relapse. At presentation, in addition to 
the abnormalities I describe in NK cells, a similar process may occur with the T cell response as 
indicated by the impairment of T cell synapsing and T cell cytotoxicity. Myeloid-derived suppressor 
cells (MDSC) derived from the leukaemic clone may also interfere with the immune response. 
MDSC are myeloid cells which proliferate in solid tumors and suppress the T cell response via a 
range of mechanisms including altering L arginine availability, inhibiting reactive oxygen species 
and inducing regulatory T cells287,288. Whether AML blasts have MDSC-like activity is as yet 
unclear, and further studies to explore this are indicated since MDSC are a potential target for 
immunotherapy.287 The presence of MDSC at AML presentation may explain the defective function 
of both T cells and NK cells11,155.  A critical question pertaining to immune regulation is whether the 
immune abnormalities normalise after remission when the leukaemic burden is minimal.  This is 
important because first remission of AML would be the most promising moment to introduce 
immunotherapy. Data presented in this thesis shows only partial normalisation of the NK response. 
Cytokines such as Il-15, an important growth factor for NK and T cells, could be used to improve 
their number and function to sustain remission.250 Antibody therapies targeting antigens common to 
leukaemia cells such as CD33289 are also proving useful for prolonging remission in some AML 
patients.290 At relapse, there is evidence that the immune system has again been disabled. This raises 
the question whether the treatment itself may play a role in disabling immunity. 
Chemotherapy may affect the immune system positively or negatively. While cytarabine and 
daunorubicin directly kill tumour cells and stop cell division, the effects on the immune system are 
poorly studied. Reducing leukaemic bulk may help normalise immune function but chemotherapy 
can also induce lymphopenia. For example, after AML chemotherapy in children, B cell depletion 
reduces influenza vaccine responses.291 NK cells are produced in the marrow and unlike T cells, do 
not have a significant peripheral stem cell memory pool. Indeed some T cells capable of clonogenic 
proliferation remain after induction.292 In contrast, NK cells may be more severely depleted by 
chemotherapy. Chemotherapy may, nevertheless, have favourable effects on the immune response - 
T cells are more responsive after chemotherapy and have greater proliferative potential,293 because 
lymphodepletion provides a cytokine rich environment conducive to the proliferation of tumour 
specific T cells. This lymphopenic drive has been exploited for adoptive cell transfer in both mice 
and men.294-296 After AML chemotherapy, improved cytokine release by T cells, particularly of 
antileukaemic IFNγ has been reported.297 The removal of immune cells which compete with tumour 
specific T cells for cytokines (a phenomenon known as ‘the cytokine sink’) is another benefit of 
chemotherapy.294 Finally, although it inhibits regeneration of bone marrow stromal cells,242 
chemotherapy may improve the function of antigen presenting cells, killing tumour cells by 
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apoptosis so increasing APC uptake and presentation of tumour antigens to T cells,298,299 and by 
activating APC either by release of LPS into the bloodstream through damaged mucosal barriers300 
or via release of APC-stimulating pro-inflammatory cytokines such as TNFα.301  
Much needs to be learned about the specific immune modulating effects of conventional 
chemotherapy and newer agents: certain drugs are more helpful in augmenting immune effects 
against leukaemia than others. Fludarabine, an effective antileukaemic drug which augments the 
effect of cytarabine302 induces lymphopenia and the subsequent increase in IL-15, causing a burst of 
T and NK cell regeneration.197,292 Cyclophosphamide successfully reduces regulatory T cells which 
suppress tumour immunity303 and 5 Azacytidine increases tumour antigen presentation.304 Even 
steroids, well known for their immunosuppression, can be beneficial by inhibiting the transcription 
of genes involved in immune cell effector functions, a function useful in the treatment of 
inflammatory and autoimmune disease. In keeping with this, steroids reduce NK cell cytotoxicity.305 
Recently, however, endogenous steroids have been shown to promote the appropriate selection of a 
desirable thymic T cell repertoire.306 The anti-proliferative agents such as mycophenolate mofetil, 
cyclosporin, azathiprine, tacrolimus and rapamycin are also likely to have complex beneficial and 
detrimental immune effects. Lenalidomide, the immune-modulatory drug developed as a TNFα 
blocker, is of particular interest. Lenalidomide can render the marrow microenvironment less 
hospitable to myeloma, (reviewed in307) and directly kill mutated cells in MDS (reviewed in308). It 
also stimulates T cells, and improves NK function via increased T cell IL-2 production and a direct 
effect on NK cell-mediated cytotoxicity.309-311 Therapy with cytokines such as IL-15 can also 
improve NK proliferation and function in the bone marrow.312,313  
In conclusion, for many reasons, AML has proven to be relatively resistant to treatment. However 
the disease may yield to a combined attack with chemotherapy, new "biological" agents and 
immunotherapy. Within the next decade, I anticipate considerable progress in improving the cure 
rate of this major leukaemia of older individuals by coordinated multi-modal treatment. 
Immunotherapy seems likely to play an important role in this.  
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Appendix: Supplementary material  
8.1 Consent form: functional study of NK cells in AML 
  
 
Directorate of Cancer Services – Division of Clinical Haematology 
Consent Form: Natural Killer (NK) Cells & Acute Myeloid Leukaemia study 
The participant should complete the whole of this sheet him or herself.  
        (please tick each statement as it applies to you) 
 
I have read the Information Sheet 
 
I have been given the opportunity to ask questions and discuss the proposed studies 
 
I have received sufficient information about these studies. 
 
I have received satisfactory answers to all my questions 
 
The consent process has been explained to me by: Prof/Dr/Mr/Mrs/Ms………………………. 
 
I understand that I am free to change my consent at any time, without having to give a 
reason and without affecting my future medical care.  
I understand that relevant sections of my medical notes and data collected during the study may be 
accessed by responsible individuals from the study Sponsor (Imperial College), NHS trust or 
regulatory authorities. I give permission for these individuals to access my records. 
 I consent to give samples for research into blood diseases for this research project 
 
and for other ethically approved projects 
 
Signed...............................................................................………          Date:............................. 
 
(NAME IN CAPITALS)............................................................................................……….. 
 
Hospital Number:…………………………………………………………………………… 
 
Physician seeking consent: signature...................................................   Date:.............................. 
 
(NAME IN CAPITALS)..............................................................................…………………… 
 
  
 
f
r
o
m
 
t
h
e
 
d
o
c
u
m
e
n
t 
o
r 
t
h
e
 
s
u
m
m
a
r
y
 
o
f 
a
n
 
i
n
t
 
f
r
o
m
 
t
h
e
 
d
o
c
u
m
e
n
t 
o
r 
t
h
e
 
s
u
m
m
a
r
y
 
o
f 
a
n
 
i
 
f
r
o
m
 
t
h
e
 
d
o
c
u
m
e
n
t 
o
r 
t
h
e
 
s
u
m
m
a
r
y
 
o
f 
a
n
 
 
f
r
o
m
 
t
h
e
 
d
o
c
u
m
e
n
t 
o
r 
t
h
e
 
s
u
m
m
a
r
y
 
o
f 
a
 
f
r
o
m
 
t
h
e
 
d
o
c
u
m
e
n
t
o
r 
t
h
 
f
r
o
m
 
t
h
e
 
d
o
c
u
m
e
n
t
o
r 
t
h
e
 
132 
 
8.2 Patient information sheet: functional study of NK cells in AML 
 
 
 
Directorate of Cancer Services – Division of Clinical Haematology  
Natural Killer (NK) Cells & Acute Myeloid Leukaemia study 
Information Sheet: Consent for Research Samples   
Laboratory Studies in Blood Diseases 
We would like to ask your permission to use samples of your blood and bone marrow for the 
purposes of medical research. Before you decide, it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the following information 
carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether or not you wish 
to take part. If you decide not to take part, your treatment will not be affected by your decision. If 
you choose to participate, your donated samples will be sent to the laboratory of Dr. Katy Rezvani at 
the Hammersmith Hospital, Imperial College London. Dr Kate Stringaris is a young haematologist 
who is studying for her PhD in Dr Rezvani’s laboratory and the results of this study will be 
submitted as part of her degree. 
 
What is the purpose of this study? 
The purpose of this study is to look at the role of the immune system in fighting malignancies 
involving blood cells. We have known for many years that the immune system is very important in 
fighting cancer. We wish to investigate this in greater detail by taking samples from patients with 
blood malignancies to look at the ability of the immune cells to specifically recognise and kill blood 
cancer cells. Natural killer cells are part of the innate immune system and appear to be particularly 
important in the response towards leukaemia. This project investigates the role of natural killer cells, 
their receptors and their function in patients with haematological malignancies before, during and 
after treatment with a view to identifying factors which may influence the natural killer cell response. 
This work may enable us to find ways to boost the immune response to leukaemia, or provide 
targetted natural killer cell infusions to improve patient outcome after standard chemotherapeutic 
approaches with the aim of reducing relapse. If you would like additional information regarding the 
exact nature of the research, we would be happy to discuss this in more detail at your request. 
 
Why have I been chosen? 
You have been diagnosed with a haematological malignancy and therefore could help with this study 
by participating. 
 
Do I have to take part? 
Your participation in this study is entirely voluntary. It is up to you to decide whether or not to take 
part. If you do decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide not to take part then this is fine and it will not affect the standard 
of care that you will receive. 
 
What will happen to me if I take part? 
As part of your treatment your doctors will be taking samples of blood and bone marrow at regular 
intervals. At first this will be to give a precise diagnosis so as to decide on your treatment. Later on 
samples will be taken to study your response to treatment. The blood samples will be removed from 
a vein in your arm and the marrow samples will be drawn from your hip.  
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We would like to ask you to donate an additional 3 tablespoons of blood once a week during your 
first month of treatment. In addition you will have a bone marrow aspirate before your treatment 
starts and another, usually after the first course of chemotherapy. We would also like to take an 
additional tablespoon of bone marrow at these times.  
 
What are the possible disadvantages of taking part? 
At no time will these additional specimens be collected if it is felt that this would jeopardise your 
health in any way or the collection of the samples required for the management of your disease. The 
research samples will be taken at the same time as samples are taken for your routine care and 
participating in this study will not require any extra tests or needles for you. 
 
What are the possible benefits of taking part? 
It is highly unlikely that our results will change any part of your treatment. However, they might 
provide us with information that improves our understanding of your disease and helps other patients 
in the future. 
 
What if something goes wrong? 
Imperial College London holds insurance policies which apply to this study.  If you experience 
serious and enduring harm or injury as a result of taking part in this study, you may be eligible to 
claim compensation without having to prove that Imperial College is at fault.  This does not affect 
your legal rights to seek compensation. If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been treated during the course of this study then you 
should immediately inform the Investigator (Dr Kate Stringaris, contact details below).  The normal 
National Health Service complaint complaints mechanisms are also available to you.  If you are still 
not satisfied with the response, you may contact the Imperial AHSC Joint Research Office.   
Will my taking part in this study be kept confidential? 
It may be necessary to compare the results from the research laboratory with the progress of your 
disease. For this reason it will not be possible to completely anonymise your samples and in addition 
we may wish to study your medical records. However we keep the information collected about you 
during the course of the research strictly confidential.  
 
What will happen to my samples? 
When your sample arrives in the laboratory, it will be given a number (known as a unique 
identification number). It will be stored under this number and not under your name. Dr. Stringaris 
will hold the information necessary to link you with the unique identification number and hence the 
sample. Any information about you which leaves the hospital will also have your name and address 
removed so that you cannot be recognised from it. Samples will be frozen and stored in liquid 
nitrogen in the department of Haematology, Hammersmith Hospital, until they are used in 
experiments. They are likely to be used within 3 years although storage time may be longer. If there 
are any remaining samples not used in this particular study, rather than disposing of them, we will 
use them in future, ethically approved studies into leukaemia. 
 
Who is organising and funding the research? 
This research project has been submitted and accepted for PhD registration at Imperial College 
London and to organisations that sponsor medical research e.g. the charity LEUKA.  
 
Who has reviewed the study? 
Before the research could be registered for a higher degree and the funding agency agreed to fund the 
research, the project was sent to other scientists working in the same area to confirm that the research 
is worthwhile and justified. The project has also been approved by the local Ethical Review Board. 
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What will happen to the results of the research studies? 
We hope that the results of our research may be published in medical and scientific journals. You 
may have copies of these publications if you wish but your name will not appear as it will be 
anonymous. If you would like an update on the progress of the research please ask Dr. Kate 
Stringaris or Dr Katy Rezvani (contact details at the end of the page). 
 
It is possible that some of the information that we obtain from our research will be of value to other 
researchers or even to commercial biotechnology companies. We may wish to enter into an 
agreement with a company such that we obtain some financial sponsorship for our work. If this were 
to happen, any information obtained from your blood samples would be completely anonymised so 
that you could not be identified. Your samples will not be used for any tests in which the information 
obtained could be used to any disadvantage by another organisation, e.g. insurance companies. If at 
any time you decide that you do not wish for your samples to be used for research purposes, then we 
will arrange for them to be discarded. 
 
Contact for Further Information: 
Dr Kate Stringaris      Dr Katy Rezvani 
Specialist Registrar/Research Fellow    Clinical senior Lecturer 
Department of Haematology      Department of Haematology 
Hammersmith Hospital      Hammersmith Hospital 
4th Floor Commonwealth Building    4th Floor Commonwealth Building 
Du Cane Road       Du Cane Road 
London W12 0HS       London W12 0HS 
Tel: 020 8383 4017.       Tel: 020 8383 2175 
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8.3 Supplementary table 1. Optimising DNA extraction 
Experiment to assess optimum cell number to use for DNA extraction method described in 2.3 
showing that above 10 x 106 cells the purity began to drop as the column became overloaded. 
No. cells from same patient 
sample applied to column 
DNA concentration acheived Purity of DNA (260/280) 
5 x 106 110.24 ng/µl 1.89 
5 x 106 143.03 ng/µl 1.87 
10 x 106 272.48 ng/µl 1.89 
20 x 106 456.8 ng/µl 1.4 
 
8.4 Supplementary table 2. Univariate analyses in Cox models for factors affecting transplant 
outcome (n=261) 
Variable No pts 
(%) 
TRM OS Relapse GVHD  (ii-iv) 
data on n=192 
Risk Group      
Standard 105 16 (15%) 75 (71%) 15 (14%) 26 (30%) 
High risk 156 39 (25%) 59 (38%) 63 (40%) 59 (57%) 
  P= 0.014* P= <0.001* P= <0.001* P= <0.001* 
CD34+ dose      
<median 5 130 38 (29%) 52 (40%) 44 (34%) 40 (47%) 
>median 5 131 17 (13%) 82 (63%) 34 (26%) 45 (43%) 
  P= 0.001* P= <0.001* P=0.033* P=0.573 
Graft type      
Bone Marrow 41 15 (37%) 18 (44%) 10 (24%)  
PBSC 220 40 (18%) 116 (53%) 68 (40%)  
  P= 0.002* P=0.123 P=0.711 P= 0.203 
Patient age      
<median 36 yrs 130 25 (19%) 70 (54%) 40 (31%) 49 (47%) 
>median 36 yrs 131 30 (23%) 64 (50%) 38 (2%) 36 (41%) 
  P= 0.466 P=0.47 P=0.9 P=0.43 
LC30      
<median 600 131 40 (31%) 61 (47%) 35 (27%) 41 (43%) 
>median 600 130 15 (12%) 73 (56%) 43 (33%) 44 (45%) 
  P=<0.001* P= 0.13 P=0.388 P=0.759 
Transplant era      
<median July 01 130 35 (26.9%) 59 (45%) 38 (29%) 45 (46.9%) 
>median July 01 131 20 (15.3%) 75 (57%) 40 (30%) 40 (42%) 
  P= 0.021* P=0.144 P=0.934 P=0.468 
Donor KIRs      
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Favourable KIRs 87 15 (17%) 51 (59%) 21 (24%) 22 (35%) 
Not favourable KIRs 159 33 (21%) 77 (48%) 53 (33%) 58 (49%) 
  P=0.350 P=0.05 P=0.043* P= 0.074 
Donor KIR Haplotype      
B 156 25 (16) 86 (55%) 46 (30%) 49 (45%) 
A                                                                                                   90 23 (26%) 42 (47%) 28 (31%) 31 (45%) 
  P=0.072 P=0.20 P=0.79 P=0.837 
No. Inhib. Donor KIRs      
< median 8 99 22 (22%) 48 (49%) 35 (35%) 31 (43%) 
>median 8 145 26 (18%) 79 (52%) 38 (26%) 49 (45%) 
  P=0.374 P=0.36 P=0.13 P=0.801 
No. activ. Donor KIRs      
<median 3 107 25 (23.4%) 56 (52%) 32 (30%) 38 (47%) 
>/=median3 138 23 (17%) 72 (52%) 41 (30%) 42 (42%) 
  P=0.218 P=0.98 P=0.97 0.472 
Missing KIR ligand      
No 76 20 (26%) 38 (50%) 20 (26%) 25 (43%) 
Yes 126 22 (18%) 65 (52%) 43 (34%) 43 (47%) 
  P=0.107 P=0.83 P=0.25 P=0.620 
No. missing ligands      
No missing ligand 76 20 (26%) 38 (50%) 20 (26.3%) 25 (43%) 
One missing 68 12 (18%) 36 (53%) 21 (31%) 24 (50%) 
Two missing 49 6 (12%) 25 (51%) 19 (39%) 16 (46%) 
  P=0.135 P=0.94 0.34 P=0.777 
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8.5 Supplementary table 3. Competing risk analysis 
 
Multiple event stratified Cox model (time to first event analysis) 
 
 Coefficient Hazard Ratio   Robust SE        P value 
Risk Group 1.52664     4.603 0.341   <0.001 
CD34 dose -0.61422     0.541 0.295 0.037 
PBSC graft 0.00447      1.004 0.464   0.99 
Patient age -0.05726      0.944 0.285 0.84 
LC30 count 0.75153      2.120 0.381   0.049 
SCT era -0.50735      0.602 0.340 0.14 
3 Favourable 
KIRs 
-1.00939      0.364 0.364 0.0056 
KIR haplotype  1.08354      2.955 0.687   0.12 
Inhib KIRs>8 -1.62430      0.197 0.483 <0.001 
Activ KIRs>3 0.78797      2.199 0.575   0.17 
Missing KIR 
ligand 
0.19691      1.218 0.292   0.5 
Liklihood ratio test p value = <0.001. 
 
8.6 Supplementary figure 1. Patient representation for NIH cohort 
Showing that the sample of patients for whom donor samples were available is representative of the 
whole patient population transplanted at the NHLBI since 1993 in terms of outcome: 
 
  
 
  
A. Relapse rates in 246 patients with 
donor samples available 
B. Relapse rates in 261 patients 
transplanted since 1993 
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